<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacotherapy for hypertension in adults 60 years or older - Musini, VM - 2019 | Cochrane Library</title> <meta content="Pharmacotherapy for hypertension in adults 60 years or older - Musini, VM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacotherapy for hypertension in adults 60 years or older - Musini, VM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000028.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacotherapy for hypertension in adults 60 years or older" name="citation_title"/> <meta content="Vijaya M Musini" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="vijaya.musini@ti.ubc.ca" name="citation_author_email"/> <meta content="Aaron M Tejani" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Ken Bassett" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Lorri Puil" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="James M Wright" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD000028.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/06/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antihypertensive Agents [therapeutic use]; *Hypertension [drug therapy]; Coronary Disease [prevention &amp; control]; Randomized Controlled Trials as Topic; Stroke [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000028.pub3&amp;doi=10.1002/14651858.CD000028.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000028\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000028\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","hr","fa","pt","ja","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000028.pub3",title:"Pharmacotherapy for hypertension in adults 60 years or older",firstPublishedDate:"Jun 5, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000028.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000028.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000028.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000028.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000028.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000028.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000028.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000028.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000028.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000028.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16105 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000028.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/appendices#CD000028-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/table_n/CD000028StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/table_n/CD000028StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacotherapy for hypertension in adults 60 years or older</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#CD000028-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vijaya M Musini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#CD000028-cr-0003">Aaron M Tejani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#CD000028-cr-0004">Ken Bassett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#CD000028-cr-0005">Lorri Puil</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information#CD000028-cr-0006">James M Wright</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information/en#CD000028-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 June 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000028.pub3">https://doi.org/10.1002/14651858.CD000028.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000028-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000028-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000028-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000028-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000028-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000028-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000028-abs-0001" lang="en"> <section id="CD000028-sec-0001"> <h3 class="title" id="CD000028-sec-0001">Background</h3> <p>This is the second substantive update of this review. It was originally published in 1998 and was previously updated in 2009. Elevated blood pressure (known as 'hypertension') increases with age ‐ most rapidly over age 60. Systolic hypertension is more strongly associated with cardiovascular disease than is diastolic hypertension, and it occurs more commonly in older people. It is important to know the benefits and harms of antihypertensive treatment for hypertension in this age group, as well as separately for people 60 to 79 years old and people 80 years or older. </p> </section> <section id="CD000028-sec-0002"> <h3 class="title" id="CD000028-sec-0002">Objectives</h3> <p><b>Primary objective</b> </p> <p>• To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on all‐cause mortality in people 60 years and older with mild to moderate systolic or diastolic hypertension </p> <p><b>Secondary objectives</b> </p> <p>• To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on cardiovascular‐specific morbidity and mortality in people 60 years and older with mild to moderate systolic or diastolic hypertension </p> <p>• To quantify the rate of withdrawal due to adverse effects of antihypertensive drug treatment as compared with placebo or no treatment in people 60 years and older with mild to moderate systolic or diastolic hypertension </p> </section> <section id="CD000028-sec-0003"> <h3 class="title" id="CD000028-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to 24 November 2017: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We contacted authors of relevant papers regarding further published and unpublished work. </p> </section> <section id="CD000028-sec-0004"> <h3 class="title" id="CD000028-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of at least one year's duration comparing antihypertensive drug therapy versus placebo or no treatment and providing morbidity and mortality data for adult patients (≥ 60 years old) with hypertension defined as blood pressure greater than 140/90 mmHg. </p> </section> <section id="CD000028-sec-0005"> <h3 class="title" id="CD000028-sec-0005">Data collection and analysis</h3> <p>Outcomes assessed were all‐cause mortality; cardiovascular morbidity and mortality; cerebrovascular morbidity and mortality; coronary heart disease morbidity and mortality; and withdrawal due to adverse effects. We modified the definition of cardiovascular mortality and morbidity to exclude transient ischaemic attacks when possible. </p> </section> <section id="CD000028-sec-0006"> <h3 class="title" id="CD000028-sec-0006">Main results</h3> <p>This update includes one additional trial (<a href="http://MRC-TMH 1985" target="_blank">MRC‐TMH 1985</a>). Sixteen trials (N = 26,795) in healthy ambulatory adults 60 years or older (mean age 73.4 years) from western industrialised countries with moderate to severe systolic and/or diastolic hypertension (average 182/95 mmHg) met the inclusion criteria. Most of these trials evaluated first‐line thiazide diuretic therapy for a mean treatment duration of 3.8 years. </p> <p>Antihypertensive drug treatment reduced all‐cause mortality (high‐certainty evidence; 11% with control vs 10.0% with treatment; risk ratio (RR) 0.91, 95% confidence interval (CI) 0.85 to 0.97; cardiovascular morbidity and mortality (moderate‐certainty evidence; 13.6% with control vs 9.8% with treatment; RR 0.72, 95% CI 0.68 to 0.77; cerebrovascular mortality and morbidity (moderate‐certainty evidence; 5.2% with control vs 3.4% with treatment; RR 0.66, 95% CI 0.59 to 0.74; and coronary heart disease mortality and morbidity (moderate‐certainty evidence; 4.8% with control vs 3.7% with treatment; RR 0.78, 95% CI 0.69 to 0.88. Withdrawals due to adverse effects were increased with treatment (low‐certainty evidence; 5.4% with control vs 15.7% with treatment; RR 2.91, 95% CI 2.56 to 3.30. In the three trials restricted to persons with isolated systolic hypertension, reported benefits were similar. </p> <p>This comprehensive systematic review provides additional evidence that the reduction in mortality observed was due mostly to reduction in the 60‐ to 79‐year‐old patient subgroup (high‐certainty evidence; RR 0.86, 95% CI 0.79 to 0.95). Although cardiovascular mortality and morbidity was significantly reduced in both subgroups 60 to 79 years old (moderate‐certainty evidence; RR 0.71, 95% CI 0.65 to 0.77) and 80 years or older (moderate‐certainty evidence; RR 0.75, 95% CI 0.65 to 0.87), the magnitude of absolute risk reduction was probably higher among 60‐ to 79‐year‐old patients (3.8% vs 2.9%). The reduction in cardiovascular mortality and morbidity was primarily due to a reduction in cerebrovascular mortality and morbidity. </p> </section> <section id="CD000028-sec-0007"> <h3 class="title" id="CD000028-sec-0007">Authors' conclusions</h3> <p>Treating healthy adults 60 years or older with moderate to severe systolic and/or diastolic hypertension with antihypertensive drug therapy reduced all‐cause mortality, cardiovascular mortality and morbidity, cerebrovascular mortality and morbidity, and coronary heart disease mortality and morbidity. Most evidence of benefit pertains to a primary prevention population using a thiazide as first‐line treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000028-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000028-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000028-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000028-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000028-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000028-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000028-abs-0015">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000028-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000028-abs-0014">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000028-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000028-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000028-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000028-abs-0005" lang="en"> <h3>Pharmacotherapy for hypertension in adults 60 years or older</h3> <p><b>Review question</b> </p> <p>This is the second update of this review, first published in 1998 and first updated in 2009. We wanted to study the benefits and harms of using blood pressure‐lowering drugs in adults 60 years or older with raised blood pressure. </p> <p><b>Search date</b> </p> <p>We searched the available medical literature to find all trials that compared drug treatment versus placebo or no treatment to examine this question. Data included in this review are up‐to‐date as of November 2017. </p> <p><b>Background</b> </p> <p>High blood pressure, which is common among elderly people 60 years or older, increases the risk of heart attack and stroke. </p> <p><b>Study characteristics</b> </p> <p>We found 16 studies that randomly assigned 26,795 patients 60 years or older with high blood pressure to antihypertensive drug therapy or to placebo or untreated control for a mean duration of 4.5 years. </p> <p><b>Key results</b> </p> <p>Blood pressure‐lowering drug therapy in people with hypertension 60 years and older reduced death, strokes, and heart attacks. Benefit was similar if both upper and lower blood pressure numbers were elevated and if only the upper number was elevated. First‐line treatment used in most studies was a thiazide. More patients withdrew from the studies owing to side effects of these drugs. The magnitude of benefit in cardiovascular mortality and morbidity observed was probably greater among 60‐ to 79‐year‐old patients than in very elderly patients 80 years or older. </p> <p><b>Conclusions</b> </p> <p>Blood pressure‐lowering drug treatment for healthy persons (60 years or older) with raised blood pressure reduces death, heart attacks, and strokes. </p> <p><b>Quality of evidence</b> </p> <p>Review authors graded the quality of evidence as high for reduction in death and as moderate for reduction in stroke and heart attacks. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000028-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000028-sec-0096"></div> <h3 class="title" id="CD000028-sec-0097">Implications for practice</h3> <section id="CD000028-sec-0097"> <p>Antihypertensive treatment in people aged 60 and older with moderate to severe systolic and/or diastolic hypertension reduces total mortality and total cardiovascular morbidity and mortality. The absolute risk reduction in cerebrovascular mortality and morbidity over 3.7 years was greater (1.8%; number needed to treat for an additional beneficial outcome (NNTB) = 56) than for coronary heart disease mortality and morbidity (1% with NNTB = 100). Evidence of benefit pertains mostly to a primary prevention population and to first‐line treatment with a thiazide. </p> <p>This comprehensive systematic review provides additional evidence that the reduction in mortality observed was mostly due to reduction in the 60‐ to 79‐year‐old patient subgroup (high‐quality evidence; risk ratio (RR) 0.86, 95% confidence interval (CI) 0.79 to 0.95). Although cardiovascular mortality and morbidity were significantly reduced in both subgroups 60 to 79 years old (moderate‐quality evidence; RR 0.71, 95% CI 0.65 to 0.77) and 80 years or older (moderate‐quality evidence; RR 0.75, 95% CI 0.65 to 0.87), the magnitude of absolute risk reduction was probably greater in 60‐ to 79‐year‐old patients (3.8% vs 2.9%). The reduction in total cardiovascular mortality was primarily due to a reduction in cerebrovascular mortality and morbidity. </p> <p>Meta‐regression by <a href="./references#CD000028-bbs2-0083" title="Bejan‐AngoulvantT , Saadatian‐ElahiM , WrightJM , SchronEB , LindholmLH , FagardR , et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta‐analysis of randomized controlled trials. Journal of Hypertension2010;28(7):1366‐72. ">Bejan‐Angoulvant 2010</a> based on the same eight randomised studies included in this review suggested that reduction in mortality was achieved in trials with the least BP reductions and the lowest intensity of therapy. This has led to the recommendation that people over 80 should be treated with low doses of a thiazide and ACE inhibitor, as was used in the only trial associated with a reduction in mortality (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>). These observations suggest that less aggressive treatment is probably a good approach in the very elderly. </p> </section> <h3 class="title" id="CD000028-sec-0098">Implications for research</h3> <section id="CD000028-sec-0098"> <p>Individual patient‐based meta‐analyses of data from existing trials should be used to derive evidence for the treatment of specific subgroups of hypertensive patients such as persons with diabetes, functional impairment, or recent stroke, or persons of African descent. Trials are needed in people with mild hypertension, resting BP 140‐159/90‐99. Further long‐term RCTs are needed to investigate which first‐line drug is best for patients 60 years or older, and to study different approaches to treatment (e.g. an RCT comparing the use of two drugs at low dose (as in the <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> trial) vs traditional antihypertensive therapy using three to four drugs in maximal doses). </p> <p>We would like to encourage researchers to provide access to data on subgroups of older patients in trial populations, either by providing aggregate data for participants age 60 years or older, or by providing individual patient data to enable such analyses by review authors in the future. Without access to data on the age group of interest in all trials, we are limited to analysing a subset of trials that do provide these data. </p> <p>More randomised controlled trials need to be done in the specific age group of hypertensive patients 60 to 79 years old, and particularly in the age group 80 years or older. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000028-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000028-sec-0036"></div> <div class="table" id="CD000028-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug compared to placebo or no treatment in adults 60 years or older</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to placebo or no treatment in adults 60 years or older</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults 60 years or older with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> <p>(93 to 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91 (0.85 to 0.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,932<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1%<br/> NNTB = 100 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 3.7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> <p>(92 to 104)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72 (0.68 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,747<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.8%<br/> NNTB = 27 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 3.7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> <p>(31 to 39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.59 to 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,042<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.8%<br/> NNTB = 56 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 2.9 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> <p>(33 to 42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78 (0.69 to 0.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,559<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.1%<br/> NNTB = 91 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse effects</p> <p>Mean duration of 4.6 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> <p>(138 to 178)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.91 (2.56 to 3.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,310<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 10.3%<br/> NNTH = 10 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARI: absolute risk increase; ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to study limitations (incomplete outcome reporting and selective outcome reporting). </p> <p><sup>b</sup>Downgraded due to high risk of selective reporting bias, as only 4 out of 16 included RCTs reported this outcome. </p> <p><sup>c</sup>Downgraded due to inconsistency (I² &gt; 50%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000028-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000028-sec-0037"></div> <section id="CD000028-sec-0038"> <h3 class="title" id="CD000028-sec-0038">Description of the condition</h3> <p>Blood pressure increases with age, and the rate of rise is greater over the age of 60. As a result, the number of people with elevated blood pressure (known as 'hypertension') increases with age. Systolic blood pressure is more strongly associated with cardiovascular disease than is diastolic blood pressure, particularly in older people. Isolated systolic hypertension occurs more commonly in older people. Older people also accumulate higher rates of other risk factors for cardiovascular disease such as obesity, left ventricular hypertrophy, sedentary lifestyle, hyperlipidaemia, and diabetes. </p> <p>Hypertension is a major risk factor for cardiovascular disease in older adults. Hypertension is present in 69% of patients with a first myocardial infarction; in 77% of those with a first stroke; in 74% of those with congestive heart failure; and in 60% of those with peripheral arterial disease (<a href="./references#CD000028-bbs2-0080" title="AronowWS . Treating hypertension and prehypertension in older people: when, whom and how. Maturitas2015;80:31‐6. ">Aronow 2015</a>). </p> <p>Uncontrolled high blood pressure can lead to heart attack, stroke, aneurysm (life‐threatening if ruptured), heart failure, kidney damage, and vision loss (due to thickened, damaged, or torn blood vessels in the eye). </p> </section> <section id="CD000028-sec-0039"> <h3 class="title" id="CD000028-sec-0039">Description of the intervention</h3> <p>Changing lifestyle ‐ eating a healthy diet with less salt, exercising regularly, quitting smoking, limiting alcohol intake, and maintaining a healthy weight ‐ can help to control high blood pressure. When these lifestyle changes are not enough, treatment with antihypertensive drugs is recommended. Practitioners use several classes of antihypertensive drugs such as diuretics, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin‐receptor blockers (ARBs), beta blockers, and calcium channel blockers to lower blood pressure. They also use other medications to treat high blood pressure, including alpha blockers, alpha‐beta blockers, centrally acting drugs, vasodilators, and aldosterone antagonists. </p> </section> <section id="CD000028-sec-0040"> <h3 class="title" id="CD000028-sec-0040">How the intervention might work</h3> <p>Following are the mechanisms of action of the most commonly used antihypertensive drug classes. </p> <p> <ul id="CD000028-list-0001"> <li> <p>Thiazide and thiazide‐like diuretics lower blood pressure over the long term through a mechanism of action that is not fully understood (<a href="./references#CD000028-bbs2-0147" title="ZhuZ , ZhuS , LiuD , CaoT , WangL , TepelM . Thiazide‐like diuretics attenuate agonist‐induced vasoconstriction by calcium desensitisation linked to rho kinase. Hypertension2005;45(2):233‐9. ">Zhu 2005</a>). After long‐term use, thiazides lower peripheral resistance. The mechanism of these effects is uncertain, as it may involve effects on 'whole body', renal autoregulation, or direct vasodilator actions (<a href="./references#CD000028-bbs2-0104" title="HughesAD . How do thiazide and thiazide‐like diuretics lower blood pressure?. Journal of the Renin‐Angiotensin‐Aldosterone System2004;5(4):155‐60. [DOI: 10.3317/jraas.2004.034] ">Hughes 2004</a>). Thiazides act on the kidney to inhibit reabsorption of sodium (Na<sup>+</sup>) and chloride (Cl<sup>‐</sup>) ions from the distal convoluted tubules in the kidneys by blocking the thiazide‐sensitive Na<sup>+</sup>‐Cl<sup>‐</sup> symporter (<a href="./references#CD000028-bbs2-0092" title="DuarteJD , Cooper‐DeHoffRM . Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide‐like diuretics. Expert Reviews on Cardiovascular Therapy2010;8(6):793‐802. ">Duarte 2010</a>). </p> </li> <li> <p>Beta blockers are competitive antagonists that block the receptor sites for epinephrine (adrenaline) and norepinephrine on adrenergic beta receptors. Some block activation of all types of beta‐adrenergic receptors (β<sub>1</sub>, β<sub>2</sub>, and β<sub>3</sub>), and others are selective for one of the three types of beta receptors (<a href="./references#CD000028-bbs2-0095" title="FrishmanWH , Cheng‐LaiA , NawarskasJ . Current Cardiovascular Drugs. Fourth. London, UK: Current Science Group, 2005. ">Frishman 2005</a>). </p> </li> <li> <p>ACE inhibitors block the conversion of angiotensin I (AI) to angiotensin II (AII) and thus decrease the actions of angiotensin II. The end result consists of lowered arteriolar resistance and increased venous capacity; decreased cardiac output, cardiac index, stroke work, and volume; lowered resistance in blood vessels of the kidneys; and increased excretion of sodium in the urine. Renin and AI are increased in concentration in the blood as a result of negative feedback on conversion of AI to AII. Levels of AII and aldosterone are decreased. Bradykinin is increased because ACE is responsible for inactivation of bradykinin. </p> </li> <li> <p>Angiotensin‐receptor blockers (ARBs) block the activation of angiotensin II AT<sub>1</sub> receptors. Blockage of AT<sub>1</sub> receptors directly causes vasodilation, reduces secretion of vasopressin, and reduces production and secretion of aldosterone. </p> </li> <li> <p>Calcium channel blockers block the calcium channel and inhibit calcium ion influx into vascular smooth muscle and myocardial cells. They reduce blood pressure through various mechanisms including vasodilation, reduction in the force of contraction of the heart, slowing of the heartbeat, and direct reduction of aldosterone production. </p> </li> <li> <p>Alpha<sub>1</sub>‐adrenergic receptor blockers inhibit the binding of norepinephrine (noradrenaline) to α<sub>1</sub> receptors on vascular smooth muscle cells. The primary effect of this inhibition is vasodilation, which decreases peripheral vascular resistance, leading to decreased blood pressure. </p> </li> <li> <p>Central sympatholytic drugs reduce blood pressure mainly by stimulating central α<sub>2</sub>‐adrenergic receptors in the brainstem centres, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and the peripheral circulation. </p> </li> <li> <p>Vasodilators act directly on the smooth muscle of arteries to relax their walls so blood can move more easily through them. </p> </li> </ul> </p> </section> <section id="CD000028-sec-0041"> <h3 class="title" id="CD000028-sec-0041">Why it is important to do this review</h3> <p>Most of the early trials evaluating antihypertensive drug therapy were conducted in lower‐risk people younger than 60 years. The first definitive clinical trial evidence supporting blood pressure‐lowering treatment was produced in the mid‐1980s. Before that time, policy makers and clinicians were reluctant to recommend treatment, particularly for the elderly; some regarded systolic hypertension as a natural feature of aging, and others feared excessive harm from blood pressure lowering in this age group. </p> <p>When all drug therapies are included in one review, the underlying assumption is that the benefits of lowering blood pressure are independent of the mechanism by which this is achieved. This assumption has not been proven, and it is likely that different drugs lowering blood pressure by different mechanisms will have effects that are independent of the blood pressure‐lowering effect. A drug that lowers blood pressure could have pharmacological and physiological actions independent of blood pressure lowering, and these other actions (both known and unknown) could enhance or negate effects on health outcomes associated with the decrease in blood pressure. This possibility is supported by an analysis suggesting that blood pressure lowering explains only about 50% of the treatment effect in antihypertensive trials (<a href="./references#CD000028-bbs2-0084" title="BoisselJP , GueyffierF , BoutitieF , PocockS , FagardR . Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundamentals of Clinical Pharmacology2005;19:579‐84. ">Boissel 2005</a>). </p> <p>It is important to know and compare the benefits and harms of antihypertensive drug therapy in different age groups of patients with hypertension ‐ 18 to 59 years old; and 60 years or older. Our aim is to document the best available evidence for adult patients 60 years or older. A meta‐analysis in patients 80 years or older from earlier trials by <a href="./references#CD000028-bbs2-0100" title="GueyffierF , BulpittC , Boissel , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomized controlled trials. Lancet1999;353(9155):793‐6. ">Gueyffier 1999</a> showed a trend towards increased mortality. Therefore we planned subgroup analyses of patients 60 to 79 years old, and 80 year or older. This is the second substantive update of this review. It was originally published as <a href="./references#CD000028-bbs2-0149" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a>, and the first update was published as <a href="./references#CD000028-bbs2-0151" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>. </p> <p>A Cochrane Review titled "Pharmacotherapy for hypertension in adults age 18 to 59 years old" was published recently (<a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>). A Cochrane Review titled "First line drugs for hypertension" has recently been updated (<a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000028-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000028-sec-0042"></div> <section id="CD000028-sec-0043"> <h3 class="title" id="CD000028-sec-0043">Primary objective</h3> <p> <ul id="CD000028-list-0002"> <li> <p>To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on all‐cause mortality in people 60 years and older with hypertension defined as blood pressure greater than 140/90 mmHg. </p> </li> </ul> </p> </section> <section id="CD000028-sec-0044"> <h3 class="title" id="CD000028-sec-0044">Secondary objectives</h3> <p> <ul id="CD000028-list-0003"> <li> <p>To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on cardiovascular‐specific morbidity and mortality in people 60 years and older with hypertension defined as blood pressure greater than 140/90 mmHg. </p> </li> <li> <p>To quantify the rate of withdrawal due to adverse effects of antihypertensive drug treatment as compared with placebo or no treatment in people 60 years and older with hypertension defined as blood pressure greater than 140/90 mmHg. </p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000028-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000028-sec-0045"></div> <section id="CD000028-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000028-sec-0047"> <h4 class="title">Types of studies</h4> <p>We included only parallel‐group randomised controlled trials (RCTs) of at least one year's duration. Trials must have included a control group that received a placebo or received no antihypertensive treatment. We excluded trials that compared two specific antihypertensive treatments without a placebo or an untreated control. </p> <p>We excluded trials using other than randomised allocation methods such as alternate allocation, week of presentation, or retrospective controls. </p> </section> <section id="CD000028-sec-0048"> <h4 class="title">Types of participants</h4> <p>Trials must include only people 60 years of age or older or must separately report outcomes for people 60 or older. Researchers must measure blood pressure using the proper technique at least two times with the participant resting for at least five minutes. Participants must have a systolic blood pressure of at least 140 mmHg and/or a diastolic blood pressure of at least 90 mmHg at baseline. </p> </section> <section id="CD000028-sec-0049"> <h4 class="title">Types of interventions</h4> <p>Acceptable antihypertensive drug treatments include angiotensin‐converting enzyme inhibitors, angiotensin‐receptor antagonists, beta‐adrenergic blockers, combined alpha and beta blockers, calcium channel blockers, diuretics, alpha‐adrenergic blockers, central sympatholytics, direct vasodilators, and peripheral adrenergic antagonists. Investigators could have administered drugs alone or in combination or in fixed or stepped up regimens. </p> </section> <section id="CD000028-sec-0050"> <h4 class="title">Types of outcome measures</h4> <section id="CD000028-sec-0051"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000028-list-0004"> <li> <p>All‐cause mortality</p> </li> </ul> </p> </section> <section id="CD000028-sec-0052"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000028-list-0005"> <li> <p>Cardiovascular morbidity and mortality* including total stroke, total coronary heart disease, hospitalisation or death from congestive heart failure, and other significant vascular deaths such as ruptured aneurysm </p> <ul id="CD000028-list-0006"> <li> <p>This does not include angina, transient ischaemic attacks, surgical or other procedures, or accelerated hypertension </p> </li> </ul> </li> <li> <p>Cerebrovascular morbidity and mortality including fatal and non‐fatal stroke</p> </li> <li> <p>Coronary heart disease (CHD) morbidity and mortality including fatal and non‐fatal myocardial infarctions and sudden or rapid cardiac death </p> </li> <li> <p>Withdrawal due to adverse effects</p> </li> </ul> </p> <p>The original review reported data using different definitions of cardiovascular mortality and morbidity as defined in each individual included study (<a href="./references#CD000028-bbs2-0148" title="MulrowCD , CornellJA , HerreraCR , KadriA , FarnettL , AguilarC . Hypertension in the elderly: Implications and generalizability of randomized trials. JAMA1994;272:1932‐8. ">Mulrow 1994</a>). Refer to <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a>. </p> <p>Please note that for this second substantive update, we have modified the definition of cardiovascular mortality and morbidity to exclude transient ischaemic attacks (TIAs) as much as possible (because we judge TIA to be a subjective and less serious outcome). However, when it was not possible to exclude TIA from the total cardiovascular outcome as reported in <a href="./references#CD000028-bbs2-0149" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a>, we report overall effect size in two ways ‐ by including these studies and by deselecting them. We have standardised this update in terms of outcomes and trial identification for consistency with the two complementary reviews (<a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>; <a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> </section> </section> </section> <section id="CD000028-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000028-sec-0054"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist conducted systematic searches of the following databases for RCTs without language, publication year, or publication status restrictions. </p> <p> <ul id="CD000028-list-0007"> <li> <p>Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS Web; searched 24 November 2017). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS Web; searched 24 November 2017). </p> </li> <li> <p>MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 24 November 2017). </p> </li> <li> <p>Embase Ovid (searched 24 November 2017).</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 24 November 2017). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) (searched 24 November 2017). </p> </li> </ul> </p> <p>The Cochrane Hypertension Information Specialist modelled subject strategies for databases using the search strategy designed for MEDLINE. When appropriate, we combined these strategies with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Box 6.4.b) (<a href="./references#CD000028-bbs2-0101" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We translated the MEDLINE search strategy for use with other databases using the appropriate controlled vocabulary, as applicable (<a href="./appendices#CD000028-sec-0102">Appendix 1</a>). We applied no language restrictions. </p> <p>The databases searched in the original review and in the first update are presented in <a href="./appendices#CD000028-sec-0103">Appendix 2</a>. </p> </section> <section id="CD000028-sec-0055"> <h4 class="title">Searching other resources</h4> <p>We used previously published meta‐analyses on treatment of hypertension to identify references to trials (<a href="./references#CD000028-bbs2-0090" title="DavidsonRA , CaranasosGJ . Should the elderly hypertensive be treated? Evidence from clinical trials. Archives of Internal Medicine1987;147:1933‐7. ">Davidson 1987</a>; <a href="./references#CD000028-bbs2-0127" title="StaessenJ , FagardR , VanHoofR , AmeryA . Mortality in various intervention trials in elderly hypertensive patients: a review. European Heart Journal1988;9(2):215‐22. ">Staessen 1988</a>; <a href="./references#CD000028-bbs2-0089" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335(8693):827‐38. ">Collins 1990</a>; <a href="./references#CD000028-bbs2-0128" title="StaessenJ , FagardR , VanHoofR , AmeryA . Intervention trials in elderly hypertensive patients: a review. Journal of Hypertension1990;8(4):S63‐7. ">Staessen 1990a</a>; <a href="./references#CD000028-bbs2-0129" title="StaessenJ , AmeryA , FagardR . Isolated systolic hypertension in the elderly. Journal of Hypertension1990;8(5):393‐405. ">Staessen 1990b</a>; <a href="./references#CD000028-bbs2-0111" title="LeonettiG , CuspidiC , FastidioM , LonatiL , ChiancaR . Arterial hypertension as a risk factor in the elderly and its treatment. Journal of Hypertension1992;10(2):S3‐7. ">Leonetti 1992</a>; <a href="./references#CD000028-bbs2-0133" title="ThijsL , FagardR , LijnenP , StaessenJ , VanHoofR , AmeryA . A meta‐analysis of outcome trials in elderly hypertensives. Journal of Hypertension1992;10(10):1103‐9. ">Thijs 1992</a>; <a href="./references#CD000028-bbs2-0088" title="CelisH , FagardR , StaessenJ , ThijsL , AmeryA . The older hypertensive: assessment and treatment. Netherlands Journal of Medicine1993;43:S66‐77. ">Celis 1993</a>; <a href="./references#CD000028-bbs2-0113" title="MacMahonS , RogersA . The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clinical and Experimental Hypertension1993;15(6):967‐78. ">MacMahon 1993</a>; <a href="./references#CD000028-bbs2-0105" title="InsuaJT , SacksHS , LauTS , LauJ , ReitmanD , PaganoD , et al. Drug treatment of hypertension in the elderly: a meta‐analysis. Annals of Internal Medicine1994;121:355‐62. ">Insua 1994</a>; <a href="./references#CD000028-bbs2-0134" title="ThijsL , FagardR , LijnenP , StaessenJ , VanHoofR , AmeryA . Why is antihypertensive drug therapy needed in elderly patients with systodiastolic hypertension?. Journal of Hypertension1994;12(6):S25‐34. ">Thijs 1994</a>; <a href="./references#CD000028-bbs2-0121" title="PearceKA , FurbergCD , RushingJ . Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life?. Archives of Family Medicine1995;4(11):943‐50. ">Pearce 1995</a>; <a href="./references#CD000028-bbs2-0098" title="GueyffierF , FromentA , GoutonM . New meta‐analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. Journal of Human Hypertension1996;10:1‐8. ">Gueyffier 1996</a>; <a href="./references#CD000028-bbs2-0122" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis. JAMA1997;277(9):739‐45. ">Psaty 1997</a>; <a href="./references#CD000028-bbs2-0100" title="GueyffierF , BulpittC , Boissel , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomized controlled trials. Lancet1999;353(9155):793‐6. ">Gueyffier 1999</a>; <a href="./references#CD000028-bbs2-0124" title="QuanA , KerlikowskeK , GueyffierF , BoisselJP . Efficacy of treating hypertension in women. Journal of General Internal Medicine1999;14(12):718‐29. ">Quan 1999</a>; <a href="./references#CD000028-bbs2-0145" title="WrightJM , LeeCH , ChambersKG . Systematic review of antihypertensive therapies: does the evidence assist in choosing a first‐line drug?. Canadian Medical Association Journal1999;161(1):25‐32. ">Wright JM 1999</a>; <a href="./references#CD000028-bbs2-0085" title="Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure‐lowering drugs: results of prospectively designed overviews of randomised trials. The Lancet2000;355:1955‐64. ">BPLTTC 2000</a>; <a href="./references#CD000028-bbs2-0118" title="NikolausT , SommerN , BeckerC . Treatment of arterial hypertension with diuretics, beta‐ and calcium channel blockers in old patients. Zeitschrift fur Gerontologie und Geriatrie2000;33(6):427‐32. ">Nikolaus 2000</a>; <a href="./references#CD000028-bbs2-0123" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , et al. Health outcomes associated with various antihypertensive therapies used as first‐line agents: a network meta‐analysis. JAMA2003;289(19):2534‐44. ">Psaty 2003</a>; <a href="./references#CD000028-bbs2-0138" title="TurnbullF , Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet2003;362(9395):1527‐35. ">Turnbull 2003</a>; <a href="./references#CD000028-bbs2-0108" title="KangS , WuFY , AnN , RenM . A systematic review and meta‐analysis of the efficacy and safety of a fixed low‐dose perindopril‐indapamide combination as first‐line treatment of hypertension. Clinical Therapeutics2004;26(2):257‐70. ">Kang 2004</a>; <a href="./references#CD000028-bbs2-0082" title="TurnbullF , NealB , AlbertC , ChalmersJ , ChapmanN , CutlerJ , et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine2005;165(12):1410‐9. ">BBLTTC 2005</a>; <a href="./references#CD000028-bbs2-0116" title="TherapeuticsInitiative . Treatment of elevated blood pressure in the elderly: less is better. www.ti.ubc.ca/2008/10/31/treatment‐of‐elevated‐blood‐pressure‐in‐the‐very‐elderly‐less‐is‐better (accessed 15 April 2018). ">Musini 2008</a>; <a href="./references#CD000028-bbs2-0110" title="LawMR , MorrisJK , WaldNJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665. ">Law 2009</a>; <a href="./references#CD000028-bbs2-0096" title="GoeresLM , EckstromE , LeeDS . Pharmacology for hypertension in older adults: a systematic review. Drugs and Aging2014;31:897‐910. ">Goeres 2014</a>; <a href="./references#CD000028-bbs2-0135" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta‐analyses, and meta‐regression analyses of randomized trials. Journal of Hypertension2014;32(12):2285‐95. ">Thomopoulos 2014</a>; <a href="./references#CD000028-bbs2-0130" title="SundstromJ , ArimaH , JacksonR , TurnbullF , RahimiK , ChalmersJ , et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta‐analysis. Annals of Internal Medicine2015;162(3):184‐91. ">Sundstrom 2015</a>; <a href="./references#CD000028-bbs2-0146" title="ZanchettiA , ThomopoulosC , ParatiG . Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circulation Research2015;116(6):1058‐73. ">Zanchetti 2015</a>; <a href="./references#CD000028-bbs2-0119" title="ParsonsC , MuradMH , AndersenS , MookadamF , LabonteH . The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta‐analysis. Future Cardiology2016;12(2):237‐48. ">Parsons 2016</a>; <a href="./references#CD000028-bbs2-0131" title="TanXY , HuJB . ACEIs/ARBs for the prevention of type 2 diabetes in patients with cardiovascular diseases: a systematic review and meta‐analysis. International Journal of Clinical and Experimental Medicine2016;9(5):7624‐37. ">Tan 2016</a>; <a href="./references#CD000028-bbs2-0136" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure‐lowering treatment. 6. Prevention of heart failure and new‐onset heart failure ‐ meta‐analyses of randomized trials. Journal of Hypertension2016;34(3):373‐84. ">Thomopoulos 2016</a>; <a href="./references#CD000028-bbs2-0109" title="KızılırmakP , UresinY , OzdemirO , KilickiranB , et al. Renin‐angiotensin‐aldosterone system blockers and cardiovascular outcomes: a meta‐analysis of randomized clinical trials [Renin‐anjiyotensin‐aldosteron sistemi blokerleri ve kardiyovasküler sonuçları: Randomize klinik çalışmaların meta‐analizi]. Turk Kardiyoloji Dernegi Arsivi2017;45(1):49‐66. ">Kızılırmak 2017</a>; <a href="./references#CD000028-bbs2-0142" title="WiysongeCS , BradleyHA , VolminkJ , MayosiBM , OpieLH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub5] ">Wiysonge 2017</a>). </p> <p>We contacted experts in the field to identify any other trials that we may have missed in our search. We checked the reference lists of included studies and contacted relevant individuals for information about unpublished or ongoing studies. The first version of this review did not provide a study flow diagram. However, the review authors listed 25 studies as excluded with reasons. </p> </section> </section> <section id="CD000028-sec-0056"> <h3 class="title" id="CD000028-sec-0056">Data collection and analysis</h3> <section id="CD000028-sec-0057"> <h4 class="title">Selection of studies</h4> <p>We rejected articles on the initial screening if we could determine from the title or the abstract that the article was not a report of a randomised controlled trial, or that there was no possibility that the trial would fit the requirements of this review. Of the articles selected for further review, two review authors (VM and AT) independently assessed whether they would be included or excluded. </p> </section> <section id="CD000028-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>We abstracted data using a standard data abstraction form; dual abstraction of data from the original reports of trial results by two independent reviewers (VM and AT); and disagreements resolved by discussion. Published results of these meta‐analyses as well as data from additional trials included in the updated review were compared by two review authors (VM and AT). Any disagreements were resolved by consensus (JMW and KB). </p> <p>The actual endpoints represented by each outcome measure for each study are listed under the "Outcomes" heading of the <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a> table. Within each study, the definition of endpoints for each outcome measure is identical between treatment and control groups. The individual non‐fatal outcomes included in the composite endpoint were included as counted by the trialists of each study. Many trials did not report on how events were counted after patients were censored. Refer to personal communication with the author of <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> in the risk of bias table to find out how events were counted in that trial. </p> <p>In this update, we obtained data for <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981,</a><a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981,</a><a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>, and <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> from the original <a href="./references#CD000028-bbs2-0149" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a> and <a href="./references#CD000028-bbs2-0150" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 2000</a> reviews, and the cardiovascular mortality and morbidity outcome definition in these studies did not include transient ischaemic attack. However, data for <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> and <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> studies included TIA in total cardiovascular outcomes in the original <a href="./references#CD000028-bbs2-0149" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a> and <a href="./references#CD000028-bbs2-0150" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 2000</a>. Therefore in this review, we report overall results for total cardiovascular outcome including these two studies, as well as excluding them from the overall analysis. We excluded TIA data from total cardiovascular mortality and morbidity for several additional studies (<a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> ). </p> <p>Data for the 60‐ to 64‐year‐old patient subgroup from <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> were obtained by personal communication with Francois Gueyffier from the INDANA Group (<a href="./references#CD000028-bbs2-0100" title="GueyffierF , BulpittC , Boissel , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomized controlled trials. Lancet1999;353(9155):793‐6. ">Gueyffier 1999</a>). The cardiovascular mortality and morbidity outcome in this study does not include heart failure. </p> <p>Trial characteristics are detailed in the table <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a>. Trials that were excluded are listed in the <a href="./references#CD000028-sec-0124" title="">Characteristics of excluded studies</a> table, and the reasons for exclusion are provided. </p> </section> <section id="CD000028-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (VM and AT) independently assessed risk of bias of each included trial; a third review author (JMW) adjudicated any disagreements. We assessed risk of bias according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000028-bbs2-0102" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We assessed seven domains: randomisation and allocation concealment to assess selection bias; blinding of participants and physician to assess performance bias; blinding of the outcome assessor to assess detection bias; incomplete outcome reporting to assess attrition bias; and selective reporting of outcomes to assess selective reporting bias. We added a category ‐ industry‐sponsored bias ‐ to assess whether the study was funded by the manufacturer and conflict of interest was present, which we assessed as high risk of bias, since researchers may overestimate treatment effect (<a href="./references#CD000028-bbs2-0112" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> <section id="CD000028-sec-0060"> <h5 class="title">'Summary of findings' table</h5> <p>We used GRADEpro GDT software to prepare the 'Summary of findings' table (<a href="./references#CD000028-bbs2-0097" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org. ">GRADEpro GDT</a>). We decided to include all clinically relevant primary and secondary outcomes such as total mortality, total cardiovascular events, total stroke, total coronary heart disease, and withdrawal due to adverse events. </p> <p>We considered five factors in grading the overall quality of evidence: limitations in study design and implementation, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision in results, and high probability of publication bias. This approach specifies four levels of quality: high‐, moderate‐, low‐, and very low‐quality evidence. The highest quality rating applies to randomised trial evidence. We downgraded the quality rating by one level for each factor, up to a maximum of three levels for all factors. If we noted severe problems for any one factor (when assessing limitations in study design and implementation, in concealment of allocation, loss of blinding, or attrition over 50% of participants during follow‐up), randomised trial evidence may fall by two levels due to that factor alone. </p> </section> </section> <section id="CD000028-sec-0061"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5.3 for data synthesis and analyses (<a href="./references#CD000028-bbs2-0125" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We based quantitative analyses of outcomes on intention‐to‐treat results. We used risk ratios (RRs) with 95% confidence intervals (CIs) to combine outcomes across trials using the fixed‐effect model. If there was a statistically significant difference in any outcome measure, we presented an absolute risk reduction (ARR), along with the number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome, in the 'Summary of findings' table. This estimate, with 95% confidence intervals (CI), is considered the best point estimate of the average benefit. </p> </section> <section id="CD000028-sec-0062"> <h4 class="title">Unit of analysis issues</h4> <p>We included only randomised parallel‐group studies in the review. Randomised patients who started treatment in the control group or stopped treatment in the treatment group were still analysed in the treatment group to which they were originally randomised. For all outcome measures reported, we used data from each trial at the end of the follow‐up period mentioned in each trial, which varied from one to six years. Both pilot studies ‐ <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> and <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> ‐ had no overlap of participants with the main studies ‐ <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> and <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>, respectively. </p> </section> <section id="CD000028-sec-0063"> <h4 class="title">Dealing with missing data</h4> <p>When participants were lost to follow‐up, we used data as reported for participants who were followed until end of study in the analyses. Refer to how data were accounted for and included in each study under assessment of attrition bias in the <a href="#CD000028-sec-0074">Risk of bias in included studies</a>. </p> <p>When the primary trials did not report outcomes with exact definitions as listed above, we categorised data to minimise missing data while maintaining the intended study measures. For example, the Medical Research Council Trial of Treatment of Hypertension in Older Adults ‐ <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> ‐ includes "deaths due to hypertension" in its definition of "cardiovascular events". The broad label "deaths due to hypertension" is not included in the standard definition for "cardiovascular morbidity and mortality" listed above. We included MRCOA's results in the cardiovascular morbidity and mortality outcome measure because "deaths due to hypertension" was congruous with the concept of cardiovascular morbidity and mortality. The alternative ‐ omitting MRCOA's data ‐ would result in a more reliable measure but at the expense of accuracy of the effect estimate. The number of differences in definitions was small and is unlikely to affect results. Supporting this assumption, previous meta‐analyses found homogeneity of risk reduction among outcome measures suggesting differences in outcome definition were unlikely causes of bias. </p> <p>Similarly, despite the statement in <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> that "The intention‐to‐treat analysis was restricted to the cause and date of death because data on non‐fatal events in patients who dropped out from randomised treatment were not available", we still included data on cardiovascular and cerebrovascular and coronary heart disease mortality and morbidity as was previously done in the "First‐line drugs for hypertension" review (<a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> <p>One of the trials first included in the 2009 update ‐ <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> ‐ was not conducted according to the standards of Good Clinical Practice Guidelines and did not collect data on serious adverse events, non‐fatal myocardial infarction (MI) or heart failure (personal communication with the author). However, data on cardiovascular mortality and morbidity were reported in the trial and are included in the meta‐analysis. The cardiovascular mortality and morbidity outcome in <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> includes fatal and non‐fatal stroke, fatal MI, other fatal ischaemic heart disease, sudden death, fatal congestive heart failure, fatal atherosclerosis, fatal pulmonary embolism, fatal hypertension, and fatal aortic aneurysm but does not include TIA. </p> <p>Two trials ‐ <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> and <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> ‐ included TIA in total cardiovascular outcome, and we have reported overall effect size by including these two studies as well as by excluding them from the analysis. </p> </section> <section id="CD000028-sec-0064"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity of treatment effect between trials using a standard Chi² statistic, and we used the I² statistic to estimate the amount of heterogeneity. We used the fixed‐effect model to obtain summary statistics of pooled trials in patients 60 years or older. In case heterogeneity was found to be significant, we planned to perform sensitivity analyses using the random‐effects model. Subgroup analyses were compared using the fixed‐effect model. </p> </section> <section id="CD000028-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>Several RCTs in adults 18 years or older with hypertension met the minimum inclusion criteria. However they did not report data separately in patients 60 years or older. <a href="#CD000028-tbl-0002">Table 1</a> lists these 15 studies. </p> <div class="table" id="CD000028-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs meeting the minimum inclusion criteria but not providing data in patients ≥ 60 with hypertension</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0076" title="The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE I) Investigators. Irbesartan in patients with atrial fibrillation. New England Journal of Medicine2011;364:928‐33. ">ACTIVE I</a> 2<a href="./references#CD000028-bbs2-0076" title="The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE I) Investigators. Irbesartan in patients with atrial fibrillation. New England Journal of Medicine2011;364:928‐33. ">011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised trial comparing irbesartan 300 mg/d or double‐blind placebo in patients 55 years or older for a mean follow‐up of 4.1 years. 52% of patients had hypertension at baseline. Data are not available for hypertensive patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0081" title="BarracloughM , BaintonD , CochraneAL , et al. Control of moderately raised blood pressure: report of a co‐operative randomized controlled trial. BMJ1973;3(5877):434‐6. ">Barraclough 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind randomised placebo‐controlled trial in patients 45 to 69 years old for a mean follow‐up of 1.5 years. Data for 60‐ to 69‐year‐old patients are not available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0087" title="BullS , LoudonM , FrancisJM , JosephJ , GerryS , KaramitsosTD , et al. A prospective, double‐blind, randomized controlled trial of the angiotensin‐converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). European Heart Journal Cardiovascular Imaging2015;16(8):834‐41. ">Bull 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial in adult patients 18 years or older with moderate or severe asymptomatic aortic stenosis. 32% of patients had hypertension at baseline. Participants were randomised to ramipril 10 mg daily or placebo for 1 year. Data are not reported separately in hypertensive subgroup of patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0091" title="DREAM Trial Investigators, BoschJ , YusufS , GersteinHC , PogueJ , SheridanP , et al. Effect of ramipril on the incidence of diabetes. New England Journal of Medicine2006;355(15):1551‐62. ">DREAM 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT in participants 30 years or older without cardiovascular disease but with impaired fasting glucose levels (after an 8‐hour fast) or impaired glucose tolerance. Participants were randomised to ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and were followed for a median of 3 years. 43.7% of patients at baseline had a history of hypertension. Data are not reported for patients with hypertension who were 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0093" title="DUTCH ‐TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">DUTCH ‐TIA 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind trial comparing atenolol 50 mg daily to placebo in patients 65 years or older who had a TIA for a mean follow‐up period of 2.6 years. Data for those 60 and over with hypertension at baseline were not available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0103" title="YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. ">HOPE‐HYP 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT in patients 55 years or older with previous coronary artery disease, cerebrovascular disease, or peripheral vascular disease or diabetes plus one additional risk factor. Participants randomised to ramipril 2.5 mg titrated up to 0 mg/d or placebo. Average follow‐up was 4.5 years. Data are not reported separately for people 60 years or older with hypertension </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0107" title="The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta‐blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension1985;3(4):379‐92. ">IPPPSH 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised trial in 40‐ to 64‐year‐old patients with hypertension randomised to oxprenolol or placebo for a mean follow‐up of 3.5 years. Data are not reported separately for participants 60 to 64 years of age </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0115" title="MatersonBJ , RedaDJ , CushmanWC , MassieBM , FreisED , KocharMS , et al. Single‐drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. New England Journal of Medicine1993;328(13):914‐21. ">Materson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled study of male veterans 21 years or older with DBP of 95 to 109 mmHg. Participants randomised to placebo or to 1 of the 6 drugs ‐ HCTZ 12.5 to 50 mg/d; atenolol 25 to 100 mg/d; captopril 25 to 100 mg/d; clonidine 0.2 to 0.6 mg/d; sustained preparation of diltiazem 120 to 360 mg/d; or prazosin 4 to 20 mg/d ‐ for a period of 1 year. Morbidity and mortality outcomes not reported for different drug classes nor for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0120" title="PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. ">PATS 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in Chinese patients with mean age 60 ± 8 years. Participants were randomised to indapamide 2.5 mg/d or placebo. Data are not reported separately for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0132" title="ErikssonS , OlofssonBO , WesleyPO , et al. Atenolol for secondary prevention after stroke. Cerebrovascular Disease1995;5:21‐5. ">TEST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in 720 Swedish patients &gt; 40 years old, within 3 weeks of a stroke or transient ischaemic attack with a mean follow‐up period of 30 months. Data are not reported separately for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0137" title="ElmerPJ , GrimmR , LaingB , GranditsG , SvedsenK , VanHeelN , et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Preventive Medicine1995;24(4):378‐88. ">TOMHS 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four‐year double‐blind placebo‐controlled randomised trial in patients with mild hypertension (average blood pressure, 140/91 mmHg) aged 45 to 69 years. Participants randomised to receive nutritional‐hygienic intervention plus 1 of 6 treatments: (1) placebo; (2) diuretic (chlorthalidone); (3) beta blocker (acebutolol); (4) alpha 1 antagonist (doxazosin mesylate); (5) calcium antagonist (amlodipine maleate); or (6) angiotensin‐converting enzyme inhibitor (enalapril maleate). Morbidity and mortality events were not reported separately for the different drug treatments. Corresponding author was contacted, but data for 60‐ to 69‐year‐old patients were not provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0139" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998;317(7160):713‐20. ">UKPDS 39 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised controlled open‐label trial conducted in newly diagnosed patients 25 to 65 years old with type 2 diabetes mellitus and hypertension. Participants were randomised to captopril or atenolol or placebo and were followed for 8.4 years. Data for patients 60 to 65 years old are not reported separately </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0140" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, clorisondamine, mecamylamine, and pentolinium tartrate. Archives of Internal Medicine1962;110(2):222‐29. ">VA Coop 1962</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled study of 1 year's duration in 759 hypertensive patients. The study recruited men less than 70 years old. This study did not report results separately for those 60 to 69 years old </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0141" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐34. ">VA‐I 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in ambulatory patients in the USA with mean age 51 years. Age range not reported. Participants were randomised to hydrochlorothiazide 100 mg plus reserpine 0.2 mg plus hydralazine 75 mg or 150 mg or placebo. Mean follow‐up was 1.5 years. Data for patients 60 years or older are not reported separately </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0143" title="WolfFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. Journal of Chronic Diseases1966;19(3):227‐40. ">Wolf 1966</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind placebo‐controlled trial conducted in ambulatory patients in the USA with mean age 50 years. Participants were randomised to reserpine 0.25 mg t.i.d., chlorothiazide 0.5 g b.i.d., or hydrochlorothiazide 25 mg q.i.d. plus guanethidine if needed or placebo. Mean follow‐up was 2 years. Data for patients 60 years or older are not reported separately </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DBP: diastolic blood pressure.</p> <p>HCTZ: hydrochlorothiazide.</p> <p>RCT: randomised controlled trial.</p> <p>TIA: transient ischaemic attack.</p> </div> </div> <p>We had planned to use a funnel plot to assess the possibility of publication bias for outcomes that were reported in 10 or more studies. A test for funnel plot asymmetry (small‐study effects) formally examines whether the association between estimated intervention effects and a measure of study size is greater than might be expected to occur by chance, one cause of which is publication bias. </p> </section> <section id="CD000028-sec-0066"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5.3 to perform data synthesis and analyses (<a href="./references#CD000028-bbs2-0125" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We presented dichotomous outcomes as RRs with 95% CIs using a fixed‐effect model. </p> </section> <section id="CD000028-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>A meta‐analysis in patients 80 years or older from earlier trials ‐ <a href="./references#CD000028-bbs2-0100" title="GueyffierF , BulpittC , Boissel , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomized controlled trials. Lancet1999;353(9155):793‐6. ">Gueyffier 1999</a> and <a href="./references#CD000028-bbs2-0083" title="Bejan‐AngoulvantT , Saadatian‐ElahiM , WrightJM , SchronEB , LindholmLH , FagardR , et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta‐analysis of randomized controlled trials. Journal of Hypertension2010;28(7):1366‐72. ">Bejan‐Angoulvant 2010</a> ‐ showed a trend towards increased mortality. Therefore, we planned analyses in subgroups of patients 60 to 79 years old and 80 years or older and assessed differences among subgroups using an interaction test. Furthermore, two randomised trials ‐ <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> ‐ were specifically done in the 80 years or older group of patients and were included in the first update. A Cochrane Review on the specific age group of young adults (18 to 59 years) has been recently published (<a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>), and the Cochrane Review on "First line drugs for hypertension" in adult patients 18 years or over has been recently updated (<a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> <p>When heterogeneity was estimated to be significant (I² &gt; 50%), we attempted to identify trials that would contribute to heterogeneity and to explore their population characteristics, baseline blood pressure (BP), blinded or open‐label study design, use of antihypertensive drugs as fixed dose or stepped up therapy, or response to placebo that would possibly explain the reason for heterogeneity. </p> </section> <section id="CD000028-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p>To test for robustness of results, we conducted several sensitivity analyses. We analysed data using random‐effects models. Other sensitivity analyses included restricting meta‐analysis to trials that were blinded (participant and/or provider) and to trials that contained a placebo control only. We also analysed results when removing trials that had enrolled populations restricted to persons who had previously suffered a stroke. We analysed results of trials restricted to persons with isolated systolic hypertension both as a separate group and combined with trials also assessing persons with both systolic and diastolic hypertension. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000028-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000028-sec-0069"></div> <section id="CD000028-sec-0070"> <h3 class="title">Description of studies</h3> <p>See <a href="#CD000028-fig-0001">Figure 1</a> for the PRISMA flow diagram. </p> <div class="figure" id="CD000028-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000028-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD000028-sec-0071"> <h4 class="title">Results of the search</h4> <p>The updated search strategy until November 2017 resulted in 11,855 new citations. Titles and abstracts were screened, and 11,500 were excluded. The remaining 356 full‐text articles were retrieved. None of them met the minimum inclusion criteria mostly because they did not have a placebo or no treatment comparison group; were not one year in duration; or did not have a true no treatment control group. </p> <p>The <a href="./references#CD000028-bbs2-0149" title="MulrowCD , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a> original review included 15 studies. In the first update, 13 of the original studies were included and 2 studies ‐ <a href="./references#CD000028-bbs2-0022" title="CasigliaE , SpolaoreP , MazzaA , GinocchioG , ColangeliG , OnestoC , et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Japanese Heart Journal1994;35(5):589‐600. ">CASTEL 1994</a> and <a href="./references#CD000028-bbs2-0030" title="Hypertension Detection and Follow‐up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(2 Pt 2):I198‐206. ">HDFP 1984</a> ‐ were excluded, as explained in <a href="./references#CD000028-sec-0124" title="">Characteristics of excluded studies</a>. In addition to the 13 studies in the original review, the first update included 2 new studies ‐ <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> and <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> ‐ which exclusively studied patients 80 years or older with hypertension. </p> <p>For this update, we were able to add the <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> study because data on clinical outcomes for participants 60 to 64 years old were kindly provided by Francois Gueyffier from the INDANA Group (<a href="./references#CD000028-bbs2-0100" title="GueyffierF , BulpittC , Boissel , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomized controlled trials. Lancet1999;353(9155):793‐6. ">Gueyffier 1999</a>). </p> <p>A total of 116 reports of 16 studies met the inclusion criteria and are included in this second update. <a href="#CD000028-tbl-0002">Table 1</a> lists 15 additional studies that meet the minimum inclusion criteria but do not provide aggregate data for the 60 years or older subgroup of participants. A future update may consider adapting the protocol and requesting this data for individual patient data (IPD) analysis. </p> </section> <section id="CD000028-sec-0072"> <h4 class="title">Included studies</h4> <p>Sixteen trials (N = 26,795) in healthy ambulatory adults 60 years or older with moderate to severe systolic and/or diastolic hypertension (average 182/95 mmHg) met the inclusion criteria. Most of these trials evaluated first‐line thiazide diuretic therapy for a mean treatment duration of 3.8 years (<a href="#CD000028-tbl-0003">Table 2</a>). </p> <div class="table" id="CD000028-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Details of studies meeting the inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>(N = randomised 60 years or older)</b> </p> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline SBP/DBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> <p><b>(range), years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Antihypertensive drug treatment used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> </p> <p><b>(N = 582)</b> </p> <p><b>Double‐blind</b> </p> <p><b>(identified as ANBP 1981 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> <p>(60 to 69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ chlorothiazide 500 mg, second‐line ‐ dose increased to 1000 mg, or addition of methyldopa, propranolol, or pindolol. Third‐line drugs added were hydralazine or clonidine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> </p> <p><b>(N = 48)</b> </p> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> <p>(60 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> <p>(untreated control group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bendrofluazide (93%), methyldopa, and debrisoquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a><sup>a</sup> </p> <p><b>(N = 884)</b> </p> <p><b>Open‐label</b> </p> <p><b>(identified as HEP 1986 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196/99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> <p>(60 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ atenolol 100 mg daily; second‐line ‐ bendrofluazide 5 mg daily; third‐line ‐ methyldopa 500 mg daily; fourth‐line ‐ any recognised therapy </p> <p>In the last 2 years of the trial, several participants were treated with nifedipine retard 20 mg morning and night </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> </p> <p><b>(N = 840)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ hydrochlorothiazide 25 to 50 mg + triamterene 50 to 100 mg daily; second‐line ‐ methyldopa 250 to 2000 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> </p> <p><b>(N = 200)</b> </p> <p><b>Double‐blind</b> </p> <p><b>(identified as HTN‐COOP 1976 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deserpidine 1 mg plus methyclothiazide 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> </p> <p><b>(N = 3845)</b> </p> <p><b>Double‐blind</b> </p> <p><b>80 years or older</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> <p>(80 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line‐ indapamide 1.5 mg daily; second‐line ‐ perindopril 2 mg daily; third‐line ‐ perindopril 4 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> </p> <p><b>(N = 1283)</b> </p> <p><b>Open‐label</b> </p> <p><b>80 years or older</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> <p>(80 to 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ diuretic (usually bendrofluazide 2.5 mg), an ACE inhibitor (usually lisinopril 2.5 mg), or no treatment; second‐line ‐ involved doubling the dose of the first drug; third‐line ‐ involved adding diltiazem slow‐release 120 mg daily; fourth‐line ‐ involved adding diltiazem slow‐release 240 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> </p> <p><b>(N = 91)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> <p>(&gt; 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ trichlormethiazide 1 to 4 mg; 80% monotherapy;</p> <p>second‐line ‐ reserpine (0.3 mg), methyldopa (125 to 500 mg), and hydralazine (50 to 100 mg) added </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> </p> <p><b>(N = 4396)</b> </p> <p><b>Single‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> <p>(60 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic arm:</p> <p>First‐line ‐ hydrochlorothiazide 25 mg or 50 mg + amiloride 2.5 mg or 5 mg daily; second‐line ‐ atenolol 50 mg daily; </p> <p>third‐line ‐ nifedipine up to 20 mg daily; fourth‐line ‐ other drugs</p> <p>Beta blocker arm:</p> <p>First‐line ‐ atenolol 50 mg daily; second‐line ‐ hydrochlorothiazide 25 mg or 50 mg + amiloride 2.5 mg or 5 mg daily; third‐line ‐ nifedipine up to 20 mg daily; fourth‐line ‐ other drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> </p> <p><b>60‐ to 64‐year‐old subgroup</b> </p> <p><b>(N = 2813)</b> </p> <p><b>Single‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in this subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bendrofluazide 10 mg daily, propranolol 80 to 240 mg daily; methyldopa added if required</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> </p> <p><b>(N = 4736)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ chlorthalidone 12.5 or 25 mg daily; second‐line ‐ atenolol 25 or 50 mg or reserpine 0.05 or 0.10 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> </p> <p><b>(N = 551)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fisrt‐line ‐ chlorthalidone 25 to 50 mg daily (87%); second‐line ‐ hydralazine 25 mg twice daily, reserpine 0.05 mg twice daily, or metoprolol 50 mg twice daily (13%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a><sup>a</sup> </p> <p><b>(N = 123)</b> </p> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199/106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methyldopa 250 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a><sup>a</sup> </p> <p><b>(N = 1627)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> <p>(70 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ atenolol 50 mg daily or hydrochlorothiazide 25 mg + amiloride 2.5 mg daily, or metoprolol 100 mg daily, or pindolol 5 mg daily; second‐line ‐ patients on a beta blocker received diuretics, and those on diuretics received a beta blocker </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> </p> <p><b>(N = 4695)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ nitrendipine 10 mg daily, 10 mg BID, 20 mg BID;</p> <p>second‐line ‐ enalapril 5 mg, 10 mg, 20 mg daily in evening and/or hydrochlorothiazide 12.5 to 25 mg/d in morning </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> </p> <p><b>(N = 81)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ HCTZ 100 mg plus reserpine 0.2 mg; second‐line ‐ hydralazine 75 to 150 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A total of 16 trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 26,795</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SBP ranged from 165 to199 mmHg and DBP from 75 to 106 mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age 64 to 84 years;</b> </p> <p><b>age ranged from 60 to 105 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 placebo‐controlled studies;</b> </p> <p><b>4 studies with observation as control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drugs used included thiazides, beta blockers, calcium channel blockers, ACE inhibitors, methyldopa, reserpine, hydralazine, and clonidine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Studies with baseline SBP &gt; 190 mmHg. </p> <p>ACE: angiotensin‐converting enzyme.</p> <p>CHD: coronary heart disease.</p> <p>DBP: diastolic blood pressure.</p> <p>SBP: systolic blood pressure.</p> </div> </div> <p>For most participants included in this review, mean age ranged from 64 to 84 years. Two trials did not report mean age (<a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>). Four trials originally included both younger and older persons (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>). Only data on those older than 60 are reported from these trials. The average age across trials was 73.8 years. Seven trials evaluated participants over 60 years of age (<a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). The Swedish Trial in Old Patients with Hypertension specifically evaluated people over age 70 (<a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>). The <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> trials studied patients 80 years or older. In all, 14,663 participants (54.7%) were female. </p> <p>Most trials were conducted in Western industrialised countries ‐ USA (20%), UK (32%), European multi‐site trials (40%), Sweden (5%), Australia (2%), and Japan (&lt; 1%) ‐ and evaluated first‐line diuretics (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981;</a><a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981;</a><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992;</a><a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>). <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> recruited patients from Bulgaria (88%), Spain (3%), Romania (3%), UK (2.5%), and Poland (1.5%), and from other countries in smaller numbers (Finland, Lithuania, Ireland, Greece, and Serbia). <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> recruited patients from Western Europe (2.2%), Eastern Europe (55.8%), China (39.6%), Australasia (0.5%), and Tunisia (1.9%). </p> <p>Five trials evaluated beta blocker therapies (<a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>). <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> evaluated thiazides as well as ACE inhibitors versus placebo. No randomised controlled trial comparing alpha‐adrenergic blockers or angiotensin‐receptor blockers to placebo or untreated controls was identified. </p> <p>The four trials based in the USA reported ethnicity as African American: <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (14%); <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (18% non‐white); <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> (41%); and <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (78%). All participants in <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> and <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> were white. Ten trials did not report ethnicity (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a><a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). </p> <p>Study populations predominantly consisted of ambulatory patients recruited from the community or from primary care facilities. A small proportion (6%) of patients were recruited from hospitals or homes for the aged. Studies did not consistently report data on pre‐existing conditions among participants; available data follow. Two studies were limited to stroke survivors (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>). Six other trials reported the baseline prevalence of stroke. The sample size‐based weighted average prevalence across these six trials was 3.6%<i>:</i><a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (1%), <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (1.4%), <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> (3.5%), <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> (11.3%), <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> (4.5%), and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> (6.8%). Six trials reported the baseline prevalence of myocardial infarction. Average prevalence across trials was 2.3%: <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> (0.5%), <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> (1.2%), <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (4%), <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (4.9%), <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> (3.0%), and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> (3.1%). Two studies excluded patients with diabetes (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981;</a><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>), while three other trials reported the baseline prevalence. Average prevalence across trials was 9.2%: <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> (6.8%), <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (10.1%), and <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (36%). Two trials reported the baseline prevalence of hyperlipidaemia: <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (22%) and <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> (62.2%). Ten trials reported the baseline prevalence of smoking. Average prevalence across trials was 12.1%: <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> (4.2%), <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> (6.6%), <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> (7.3%), <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (11%), <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (12.7%), <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> (16.4%), <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> (17.5%), <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> (17.5%), <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> (24%), and <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (60%). Only <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> reported data on prevalence of obesity (29%). </p> <p>Entry diastolic blood pressure criteria also have varied somewhat from trial to trial. However, trials in older persons have not routinely included patients with higher diastolic blood pressure than trials in younger persons. All trials except <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> and a subgroup in <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> reported mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline. <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>, <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>, and <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> restricted recruitment to persons with isolated systolic hypertension, defined as SBP 160 to 219 mmHg and DBP &lt; 90 mmHg (<a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>), or as DBP &lt; 95 mmHg (<a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). </p> <p>Mean blood pressure at entry in the three isolated systolic hypertension trials was 172/81 mmHg. Two studies recruited persons with isolated systolic hypertension, diastolic hypertension, or systo‐diastolic hypertension (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>). <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> and <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> recruited patients with isolated systolic hypertension or systo‐diastolic hypertension. <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> recruited patients with systolic and/or diastolic hypertension (SBP &gt; 140 mmHg and DBP 90 to 109 mmHg). <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> recruited patients with persistent hypertension defined as SBP of 160 to 199 mmHg and DBP &lt; 110 mmHg. In all, 32.5% of patients in <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> had isolated systolic hypertension. The remainder of the studies required that patients' DBP be at least 90 mmHg. Mean BP at entry was 182/95 mmHg. </p> <p>See the "Participants" heading in the <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a> table for a complete description of each study's blood pressure inclusion criteria. The mean sitting SBP/DBP in <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> was 182/99.6 mmHg, and in <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> 173/90.8 mmHg. </p> <p>Thirteen of the 16 trials instituted a stepped care approach to hypertension treatment. In more than 70% of trials, a thiazide diuretic was the first‐line drug used for the treatment group. Seven trials started the treatment group exclusively on a thiazide diuretic (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981;</a><a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981;</a><a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>). <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986,</a><a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>, and <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> started the treatment group on a diuretic or a beta blocker. <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> randomised the treatment group to two arms ‐ one initially receiving diuretics, and the other initially receiving a beta blocker. <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> started the treatment group on a calcium channel blocker. <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> started one treatment arm on a diuretic, and the other treatment arm on an ACE inhibitor. Second‐ and third‐line drugs included diuretics, beta blockers, centrally acting antiadrenergic agents, peripherally acting antiadrenergic agents, vasodilators, converting‐enzyme inhibitors, and calcium channel blockers. See the "Interventions" heading in the <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a> table for a complete description of each study's drug treatment protocol. </p> <p>Four trials maintained participants on a particular therapeutic regimen (i.e. not stepped care) throughout the study. <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> treated participants with a combination diuretic ‐ centrally acting antiadrenergic agent (hydrochlorothiazide/reserpine) ‐ plus a vasodilator (hydralazine). <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> treated participants with a diuretic (methyclothiazide) and a peripherally acting antiadrenergic agent (deserpidine). <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> treated participants with a centrally acting antiadrenergic agent (methyldopa). <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> treated participants with a fixed dose of bendrofluazide10 mg or propranolol 80 to 240 mg and added methyldopa if required. </p> <p><a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> randomised participants to three groups: no treatment, diuretic‐based treatment (usually bendroflumethiazide 2.5 mg), and an ACE inhibitor (ACEI)‐based regimen (usually lisinopril 2.5 mg). To attain target blood pressure (sitting SBP &lt; 150 mmHg and sitting DBP &lt; 80 mmHg) in the actively treated groups, the dose of diuretic or ACEI could be doubled (step 2); diltiazem slow release 120 mg could be added (step 3); or diltiazem slow release 240 mg could be added (step 4). </p> <p><a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> randomised participants to either indapamide sustained release 1.5 mg or matching placebo. To reach target blood pressure (SBP &lt; 150 mmHg and DBP &lt; 80 mmHg), perindopril 2 mg or 4 mg or matching placebo could be added. </p> <p>Length of study follow‐up ranged from relatively short ‐ 1 year in <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> or 2 years in <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991,</a><a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991,</a> and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> ‐ to relatively long ‐ the rest of the trials lasted three to six years. All trials were multi‐site studies except for <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> and <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>. The mean duration of treatment was 4.5 years in adults 60 years or older; 4 years among 60‐ to 79‐year‐olds; and 2.8 years in patients 80 years of age or older. The mean duration of treatment was 3.2 years in trials with isolated systolic hypertension in patients 60 years or older. </p> <p>Twelve trials were placebo controlled (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981;</a><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>). In four trials, the control group received no treatment (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>). </p> <p>Studies included in this review allowed participants in the control group to receive antihypertensive therapy because their blood pressure exceeded pre‐set "escape" criteria. Also, a portion of participants assigned to the treatment group stopped taking their assigned medication because they had adverse drug effects, or because they achieved normal blood pressure. Percentages of participants assigned to the control group who were receiving antihypertensive medication by the end of the trial were as follows: <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> 9%; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> 17%; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> 23%; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> 27%; <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> 35%; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> 40%; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> 44%; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> 53%; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> &gt; 35%; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> 0.8%; and <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> 0.6%. The remaining five trials did not report such data. Percentages of participants assigned to the treatment group who had ceased taking antihypertensive medication by the end of the trial were as follows: <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> 33%; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> 5%; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> &gt; 35%; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> 4%; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> 0.5%; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> ‐ diuretic arm 48%; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> beta blocker arm 63%; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> 10%; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> 30%; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> 16%; and <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> 18%. The remaining five trials did not report such data. However, those in the control group who started treatment and those in the treatment group who stopped treatment were still analysed in the treatment group to which they were randomised (intention‐to‐treat analyses). </p> </section> <section id="CD000028-sec-0073"> <h4 class="title">Excluded studies</h4> <p>Two RCTs ‐ <a href="./references#CD000028-bbs2-0030" title="Hypertension Detection and Follow‐up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(2 Pt 2):I198‐206. ">HDFP 1984</a> and <a href="./references#CD000028-bbs2-0022" title="CasigliaE , SpolaoreP , MazzaA , GinocchioG , ColangeliG , OnestoC , et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Japanese Heart Journal1994;35(5):589‐600. ">CASTEL 1994</a> ‐ were included in the original 1998 version of this review but were excluded from the first update, as the control group in these studies was not an untreated or placebo control group. <a href="./references#CD000028-bbs2-0030" title="Hypertension Detection and Follow‐up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(2 Pt 2):I198‐206. ">HDFP 1984</a> was excluded because it provided a multi‐factorial intervention, and <a href="./references#CD000028-bbs2-0022" title="CasigliaE , SpolaoreP , MazzaA , GinocchioG , ColangeliG , OnestoC , et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Japanese Heart Journal1994;35(5):589‐600. ">CASTEL 1994</a> was excluded because the control group was receiving non‐specific antihypertensive therapy from their personal physician. </p> <p>A total of 58 studies were excluded from this update and are listed with reasons for exclusion under <a href="./references#CD000028-sec-0124" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD000028-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to <a href="#CD000028-fig-0002">Figure 2</a> and <a href="#CD000028-fig-0003">Figure 3</a> for visual summaries of the risk of bias assessment. </p> <div class="figure" id="CD000028-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: Each methodological quality item presented as percentages across all included studies." data-id="CD000028-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: Each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000028-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary of each included trial." data-id="CD000028-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary of each included trial.</p> </div> </div> </div> <section id="CD000028-sec-0075"> <h4 class="title">Allocation</h4> <p>In older trials, lack of reporting of the method used for randomisation or allocation concealment is common, and we assessed risk of bias in these trials as unclear. </p> <p>Randomisation was assessed as having low risk of bias in six trials (<a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), and as having unclear risk of bias in 10 trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>). </p> <p>Allocation concealment was assessed as having low risk of bias in five trials (<a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), as having unclear risk of bias in 10 trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>), and as having high risk of bias in one trial (<a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>). </p> </section> <section id="CD000028-sec-0076"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was assessed as having low risk of bias in nine trials (<a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>), and as having high risk of bias in seven trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>). </p> <p>Blinding of outcome assessors was assessed as having low risk of bias in twelve trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), and as having high risk of bias in four trials (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>). </p> </section> <section id="CD000028-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>Providing incomplete outcome data was assessed as having low risk of bias in eight trials (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), as having unclear risk of bias in two trials (<a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>), and as having high risk of bias in six trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>). </p> </section> <section id="CD000028-sec-0078"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was assessed as having low risk of bias in seven trials (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), unclear risk in three trials (<a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>), and high risk in six trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>). </p> </section> <section id="CD000028-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>Industry sponsorship was assessed as having low risk of bias in nine trials (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>), unclear risk of bias in three trials (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>), and high risk of bias in four trials (<a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>). </p> </section> </section> <section id="CD000028-sec-0080"> <h3 class="title" id="CD000028-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD000028-tbl-0001"><b>Summary of findings for the main comparison</b> Antihypertensive drug compared to placebo or no treatment in adults 60 years or older</a> </p> <p>Analyses were performed on the combined results of all 16 studies. The three trials that included only people with isolated systolic hypertension were included in the overall analyses and were also analysed separately (<a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). </p> <p><a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> reported intention‐to‐treat data for mortality only; the morbidity data reported from <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> did not undergo intention‐to‐treat analysis. The occurrence of any trial endpoint in <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> terminated participation in the study. Thus, true intention‐to‐treat data for <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> are available only for combined cardiovascular morbidity and mortality. We decided to include data for all outcomes from both <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> and <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>, similar to what was done in the Cochrane Review titled "First line drugs for hypertension" (<a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> <p>Individual differences in patient characteristics or disease severity are associated with different levels of risk to experience an adverse event. In the aggregate, these individual differences contribute to the proportion of patients we expect to experience an event within a population. Variation in level of risk in different patient populations, both within and between clinical trials, is often associated with variability in treatment outcomes (<a href="./references#CD000028-bbs2-0106" title="IoannidisJP , LauJ . The impact of high‐risk patients on the results of clinical trials. Journal of Clinical Epidemiology1997;50(10):1089‐98. ">Ioannidis 1997</a>; <a href="./references#CD000028-bbs2-0126" title="SchmidCH , LauJ , McIntoshMW , CappelleriJC . An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta‐analysis of clinical trials. Statistics in Medicine1998;17(17):1923‐42. ">Schmid 1998</a>). This average population risk is unknown but contributes to the proportion of events experienced by a placebo control group in a randomised trial. We use the term 'control rate' to describe the probability that a member of the control group experiences the adverse event, and we use this sample value to estimate the aggregate population risk for patients enrolled in a clinical trial. </p> <section id="CD000028-sec-0081"> <h4 class="title">In adults 60 years or older</h4> <section id="CD000028-sec-0082"> <h5 class="title">All‐cause mortality</h5> <p>In the 13 trials reporting mortality data for people 60 years or older, treatment caused a significant reduction in all‐cause mortality (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.85 to 0.97; participants = 25,932; studies = 13; I² = 8%). See <a href="./references#CD000028-fig-0005" title="">Analysis 1.1</a>. </p> <p>Mortality was significantly reduced due to reductions in fatal stroke and fatal CHD. See <a href="./references#CD000028-fig-0006" title="">Analysis 1.2</a> and <a href="#CD000028-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD000028-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antihypertensive drug therapy vs control in adults 60 years or older, outcome: 1.2 Cause of cardiovascular mortality." data-id="CD000028-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antihypertensive drug therapy vs control in adults 60 years or older, outcome: 1.2 Cause of cardiovascular mortality. </p> </div> </div> </div> <p>For subgroups, refer to <a href="./references#CD000028-fig-0011" title="">Analysis 2.1</a>. Investigating treatment effects between the two subgroups showed no significant differences. Tests for subgroup differences showed the following: Chi² = 2.61, df = 1 (P = 0.11), I² = 61.7%. </p> <p> <ul id="CD000028-list-0008"> <li> <p>People 60 to 79 years old (RR 0.86, 95% CI 0.79 to 0.95; participants = 19,017; studies = 9; I² = 48%); all‐cause mortality was significantly reduced in the 60‐ to 79‐year‐old subgroup. </p> </li> <li> <p>People 80 years or older (RR 0.97, 95% CI 0.87 to 1.10; participants = 6701; studies = 8; I² = 52%). </p> </li> </ul> </p> <p>Baseline risk of mortality in the control group among patients 60 to 79 years old ranged from 4% in <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> to 34.6% in <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>, and in the 80 years or older group from 0% in <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> to 71% in <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>. </p> </section> <section id="CD000028-sec-0083"> <h5 class="title">Cardiovascular mortality and morbidity (M&amp;M)</h5> <p>Five studies independently reached statistical significance (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). </p> <p>For the 15 trials reporting cardiovascular mortality and morbidity data in people 60 years of age or older, treatment caused a significant reduction with the fixed‐effect model (RR 0.72, 95% CI 0.68 to 0.77; participants = 26,747; studies = 15; I² = 65%) and with the random‐effects model (RR 0.74, 95% CI 0.66 to 0.83; participants = 26,747; studies = 15; I² = 65%). See <a href="./references#CD000028-fig-0007" title="">Analysis 1.3</a>. </p> <p>Excluding the two studies that included TIA in the definition of the outcome measure revealed a similar reduction in overall cardiovascular mortality and morbidity (RR 0.72, 95% CI 0.67 to 0.77) (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>). </p> <p>For subgroups, see <a href="./references#CD000028-fig-0012" title="">Analysis 2.2</a>. Investigating treatment effects between the two subgroups showed no significant difference. Tests for subgroup differences showed the following: Chi² = 0.49, df = 1 (P = 0.49), I² = 0%. </p> <p> <ul id="CD000028-list-0009"> <li> <p>Patients 60 to 79 years old (RR 0.71, 95% CI 0.65 to 0.77; participants = 18,484; studies = 8; I² = 45%). </p> </li> <li> <p>Patients 80 years or older (RR 0.75, 95% CI 0.65 to 0.87; participants = 6546; studies = 7; I² = 0%). </p> </li> </ul> </p> <p>Cardiovascular mortality and morbidity were significantly reduced in both subgroups.</p> <p>The test for subgroup differences indicates that there was no statistically significant subgroup effect (P = 0.49), suggesting that age does not modify the effect of antihypertensive treatment in comparison to placebo or no treatment. However, smaller numbers of trials and participants (seven trials in 6546 participants) contributed data to the 80 years or older subgroup than to the 60‐ to 79‐year‐old subgroup (eight trials in 18,484 participants), showing no heterogeneity between the two subgroups and 95% CI overlap. </p> </section> <section id="CD000028-sec-0084"> <h5 class="title">Cerebrovascular mortality and morbidity</h5> <p>Cerebrovascular mortality and morbidity were significantly reduced among patients 60 years of age or older (RR 0.66, 95% CI 0.59 to 0.74; participants = 26,042; studies = 13; I² = 0%). See <a href="./references#CD000028-fig-0008" title="">Analysis 1.4</a>. </p> <p>For subgroups, see <a href="./references#CD000028-fig-0013" title="">Analysis 2.3</a>. Investigating treatment effects between the two subgroups showed no significant difference. Tests for subgroup differences showed the following: Chi² = 0.00, df = 1 (P = 0.98), I² = 0%. </p> <p> <ul id="CD000028-list-0010"> <li> <p>Patients 60 to 79 years old (RR 0.66, 95% CI 0.58 to 0.76; participants = 18,484; studies = 8; I² = 0%). </p> </li> <li> <p>Patients 80 years of age or older (RR 0.66, 95% CI 0.52 to 0.83; participants = 6546; studies = 7; I² = 0%). </p> </li> </ul> </p> <p>Cerebrovascular mortality and morbidity were significantly reduced in both subgroups.</p> <p>The test for subgroup differences indicated that there was no statistically significant subgroup effect (P = 0.98), suggesting that age does not modify the effect of antihypertensive treatment in comparison to placebo or no treatment. However, smaller numbers of trials and participants (seven trials in 6546 participants) contributed data to the 80 years or older subgroup than to the 60‐ to 79‐year‐old subgroup (eight trials in 18,502 participants), showing no heterogeneity between the two subgroups and similar 95% CIs. </p> </section> <section id="CD000028-sec-0085"> <h5 class="title">Coronary heart disease mortality and morbidity</h5> <p>Coronary heart disease mortality and morbidity were significantly reduced in patients 60 years of age or older (RR 0.78, 95% CI 0.69 to 0.88; participants = 24,559; studies = 11; I² = 0%). See <a href="./references#CD000028-fig-0009" title="">Analysis 1.5</a>. </p> <p>For subgroups, see <a href="./references#CD000028-fig-0014" title="">Analysis 2.4</a>. Investigating treatment effects between the 2 subgroups showed no significant difference. Tests for subgroup differences showed the following: Chi² = 0.03, df = 1 (P = 0.86), I² = 0%. </p> <p> <ul id="CD000028-list-0011"> <li> <p>Patients 60 to 79 years old (RR 0.79, 95% CI 0.69 to 0.90; participants = 18,284; studies = 7; I² = 0%): coronary heart disease mortality and morbidity were significantly reduced in the 60‐ to 79‐year‐old subgroup. </p> </li> <li> <p>Patients 80 years or older (RR 0.82, 95% CI 0.56 to 1.20; participants = 5263; studies = 6; I² = 0%). </p> </li> </ul> </p> <p>The test for subgroup differences indicated that there was no statistically significant subgroup effect (P = 0.86), suggesting that age does not modify the effect of antihypertensive treatment in comparison to placebo or no treatment. However, smaller numbers of trials and participants (six trials in 5263 participants) contributed data to the 80 years or older subgroup than to the 60‐ to 79‐year‐old subgroup (seven trials in 18284 participants), showing no heterogeneity between the two subgroups and 95% CI overlap. </p> </section> <section id="CD000028-sec-0086"> <h5 class="title">Withdrawals due to adverse effects</h5> <p>The numbers of participants who dropped out of trials due to adverse drug effects often were not reported. The five trials that did report these data showed a significant increase in withdrawals due to adverse effects (RR 2.91, 95% CI 2.56 to 3.30; participants = 11,310; studies = 4; I² = 97%). The effect size was significant even when <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> with high risk of performance and detection bias as well as selective reporting bias was excluded from analyses (RR 1.71, 95% CI 1.45 to 2.00; participants = 6914; studies = 4; I² = 55%). </p> <p>The number of people withdrawing from therapy due to adverse effects varied from study to study. On average, treating 17 participants in <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> resulted in one withdrawal, whereas in <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>, treating nine participants with a diuretic and four with a beta blocker resulted in one withdrawal. In <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>, unblinded physicians made decisions regarding severity of side effects and continuation of therapy; 176 of those in the beta blocker group were withdrawn because of bradycardia. Withdrawal data for participant subgroups 60 to 79 years old and 80 years and older were not reported separately. </p> </section> </section> <section id="CD000028-sec-0087"> <h4 class="title">Sensitivity analyses</h4> <p>When we excluded studies with SBP ≥ 190 mmHg (<a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>), studies with observation as a control (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>), or studies with high risk of performance and detection bias (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>), the overall risk ratio for both mortality and cardiovascular mortality and morbidity was similar. Results were similar when the fixed‐effect or the random‐effects model was used. In the three trials restricted to persons with isolated systolic hypertension, reported benefits were similar. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000028-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000028-sec-0088"></div> <section id="CD000028-sec-0089"> <h3 class="title" id="CD000028-sec-0089">Summary of main results</h3> <p>This systematic review provides the best available evidence for antihypertensive treatment for people with elevated blood pressure who are at least 60 years of age. It is important to appreciate that the populations studied had relatively high systolic blood pressure: an average of 172/81 mmHg in the isolated systolic hypertension trials and an average of 182/95 mmHg in the other trials. The reason that diastolic blood pressure (DBP) is lower than expected is that for two trials, mean baseline DBP was 91 mmHg (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>), for two trials 86 mmHg (<a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), and for one study 77 mmHg (<a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>). DBP at baseline was not reported in two studies (<a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>). </p> <p>In this population, antihypertensive drug treatment was associated with a modest reduction in all‐cause mortality (high‐quality evidence; risk ratio (RR) 0.91, 95% confidence interval (CI) 0.85 to 0.97). This represents an absolute risk reduction (ARR) in deaths from 110 to 100 events per 1000 participants over an average duration of 3.8 years (ARR = 1%; number needed to treat for an additional beneficial outcome (NNTB) = 100) (<a href="./full#CD000028-tbl-0001">summary of findings Table for the main comparison</a>). The reduction in mortality among adults 60 years or older was due to a significant reduction in fatal stroke and in fatal myocardial infarction (MI) (<a href="#CD000028-fig-0004">Figure 4</a>). </p> <p>Cardiovascular mortality and morbidity were significantly reduced (RR 0.72, 95% CI 0.68 to 0.77). This represents an absolute reduction from 136 to 98 events per 1000 participants for a mean duration of treatment of 3.7 years (ARR = 3.8%; number needed to treat for an additional beneficial outcome = 27) (<a href="./full#CD000028-tbl-0001">summary of findings Table for the main comparison</a>). This is a smaller ARR than the 4.3% reported in the first update of this review. This smaller ARR is due to the fact that we have added data from the <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> trial, which studied patients with mild to moderate elevations in blood pressure (BP), and to the fact that we excluded transient ischaemic attack (TIA) from this outcome. The overall ARR of 3.8% as seen here is less than that found for first‐line low‐dose thiazides of 3.9%, which includes adults of all ages. To assess benefit from first‐line thiazides in adults 60 and over, we deselected all trials that did not provide first‐line thiazides. In that analysis, the effect on total cardiovascular events with first‐line thiazides in adults 60 and over from eight trials in 10,926 people was RR 0.67 (95% CI 0.61 to 0.74) with ARR 5.1% and number needed to treat for an additional beneficial outcome = 20 over 3.7 years. </p> <p>The test of interaction between the two subgroups showed no significant differences for any outcome measure. The subgroup analysis of treatment among patients 60 to 79 years or older showed significant benefit in terms of all outcomes, that is, all‐cause mortality (ARR = 1.4%; number needed to treat for an additional beneficial outcome = 72); cardiovascular mortality and morbidity (ARR = 3.8%; number needed to treat for an additional beneficial outcome = 27); cerebrovascular mortality and morbidity (ARR = 1.7%; number needed to treat for an additional beneficial outcome = 59); and coronary heart disease mortality and morbidity (ARR = 1.1%; number needed to treat for an additional beneficial outcome = 91). See <a href="#CD000028-tbl-0004">Table 3</a>. However, in the 80 years or older subgroup, a significant risk reduction was observed in cardiovascular mortality and morbidity from 115 to 86 (75 to 100) events per 1000 participants (ARR= 2.9%; number needed to treat for an additional beneficial outcome = 35) with a mean duration of 2.2 years. This was mostly due to a decrease in cerebrovascular mortality and morbidity from 52 to 35 (27 to 43) per 1000 participants (ARR = 1.7%; number needed to treat for an additional beneficial outcome = 59). See <a href="#CD000028-tbl-0005">Table 4</a>. </p> <div class="table" id="CD000028-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 60 to 79 years old with hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control in adults 60 to 79 years old with hypertension</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy ambulatory adults 60 to 79 years old with hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 4.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (75 to 90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86 (0.79 to 0.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,017<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.4%<br/> NNTB = 72 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (85 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (0.65 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,484<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.8%<br/> NNTB = 27 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (29 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.58 to 0.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,484<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.7%<br/> NNTB = 59 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (36 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (0.69 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,284<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.1%<br/> NNTB = 91 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to study limitations (incomplete outcome reporting and selective outcome reporting). </p> </div> </div> <div class="table" id="CD000028-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 80 years or older with hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control in adults 80 years or older with hypertension</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy ambulatory adults 80 years or older with hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Random‐effects model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 2.3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> <p>(124 to 157)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97 (0.87 to 1.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6701<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 2.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/> (75 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.75 (0.65 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6546<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.9%<br/> NNTB = 35 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 2.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/> (27 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.52 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6546<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.7%<br/> NNTB = 59 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 2.5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (12 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (0.56 to 1.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5263<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to inconsistency and wide confidence interval. </p> <p><sup>b</sup>Downgraded due to study limitations ‐ high risk of selective reporting bias in HYVET 2008 study. </p> </div> </div> </section> <section id="CD000028-sec-0090"> <h3 class="title" id="CD000028-sec-0090">Overall completeness and applicability of evidence</h3> <p>The evidence is applicable to healthy ambulatory adults 60 years of age or older (mean age 73.4 years) from Western industrialised countries with moderate to severe systolic and/or diastolic hypertension (average 182/95 mmHg). Most of these trials evaluated first‐line thiazide diuretic therapy for a mean treatment duration of 3.8 years. </p> <p>Trials involving older people could have varied systematically from those including younger people. Trials that included younger people were published before 1987 (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD000028-bbs2-0051" title="LerenP , HelgelandA . Oslo Hypertension Study. Drugs1986;31(1):41‐5. ">Oslo 1986</a>; <a href="./references#CD000028-bbs2-0071" title="SmithWM , US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: results of a ten year intervention trial. Circulation Research1977;40(5 Suppl 1):98‐105. ">USPHSHCSG 1977</a>; <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD000028-bbs2-0073" title="PerryHMJr , GoldmanAI , LavinMA . Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Annals of the New York Academy of Sciences1978;304:267‐88. ">VANHLBI 1978</a>). Six large trials involving older people were published after 1990 (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). Although first‐line beta blockers and thiazide diuretics were used in most trials, recent large trials in older people have usually used either lower doses of thiazides or combinations with potassium‐sparing agents. As a result, they may be associated with less toxic adverse effects. The most recent trial in the very elderly studied first‐line indapamide sustained release 1.5 mg (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>). If blood pressure remained at systolic blood pressure (SBP) &gt; 150 mmHg and diastolic blood pressure (DBP) &gt; 80 mmHg, perindopril 2 mg or 4 mg could be added to the active treatment arm. This trial showed a significant reduction in mortality (RR 0.82, 95% CI 0.69 to 0.99; ARR = 2.2%; NNTB = 48 for 2 years) and in total cardiovascular events (RR 0.71, 95% CI 0.57 to 0.87) with low doses of two antihypertensive drugs. The other trials in the very elderly used higher doses of more antihypertensive drugs and showed a trend towards increased total mortality. Although it was not possible for us to conduct a meta‐regression analysis, when heterogeneity was explored by Bejan‐Angoulvant using meta‐regression in patients 80 years of age or older based on the same eight randomised controlled trials (RCTs) in 6701 participants included in our review (<a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>), results suggested that reduction in mortality was achieved in trials with the least reductions in BP and with the lowest intensity of therapy (<a href="./references#CD000028-bbs2-0083" title="Bejan‐AngoulvantT , Saadatian‐ElahiM , WrightJM , SchronEB , LindholmLH , FagardR , et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta‐analysis of randomized controlled trials. Journal of Hypertension2010;28(7):1366‐72. ">Bejan‐Angoulvant 2010</a>). This has led to the recommendation that people over age 80 should be treated with low doses of a thiazide and angiotensin‐converting enzyme (ACE) inhibitor, as were used in the only trial associated with a reduction in mortality (<a href="./references#CD000028-bbs2-0083" title="Bejan‐AngoulvantT , Saadatian‐ElahiM , WrightJM , SchronEB , LindholmLH , FagardR , et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta‐analysis of randomized controlled trials. Journal of Hypertension2010;28(7):1366‐72. ">Bejan‐Angoulvant 2010</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>). These observations suggest that less aggressive treatment is probably a good approach in the very elderly. This approach needs to be tested in younger populations as well. </p> <p>A Cochrane Review in adults 18 to 59 years old is based on seven studies in 17,327 patients with primary hypertension (<a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>). Mean blood pressure at baseline was 160/98 mmHg, and mean duration of treatment was five years. There was no significant reduction in mortality (RR 0.94, 95% CI 0.77 to 1.13) nor in coronary heart disease (RR 0.99, 95% CI 0.82 to 1.19). However, a significant decrease was seen in cardiovascular mortality and morbidity (RR 0.78, 95% CI 0.67 to 0.91), with an ARR of 0.9% (NNTB = 112), which was mainly due to a significant decrease in cerebrovascular mortality and morbidity (RR 0.46, 95% CI 0.34 to 0.64), with an ARR of 0.7% (NNTB = 143). The magnitude of ARR in younger adults 18 to 59 years old is much lower (ARR = 0.9%) than in adults 60 years or older (ARR = 3.8%) and in adults 60 years or older treated with first‐line thiazides (ARR = 5.1%). </p> <p>The magnitude of benefit depends on multiple factors including the baseline risk of cardiovascular complications of hypertension (<a href="./references#CD000028-bbs2-0099" title="GueyffierF , BoutitieF , BoisselJP , PocockS , CoopeJ , CutlerJ , et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta‐analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Annals of Internal Medicine1997;126(10):761‐7. ">Gueyffier 1997</a>). People with more cardiovascular risk factors (e.g. diabetes, family history of heart disease, left ventricular hypertrophy) have a greater likelihood of a reduction in cardiovascular events by antihypertensive therapy. The five‐year absolute morbidity and mortality benefit of antihypertensive therapy is greater for older than for younger adults (<a href="./references#CD000028-bbs2-0089" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335(8693):827‐38. ">Collins 1990</a>; <a href="./references#CD000028-bbs2-0148" title="MulrowCD , CornellJA , HerreraCR , KadriA , FarnettL , AguilarC . Hypertension in the elderly: Implications and generalizability of randomized trials. JAMA1994;272:1932‐8. ">Mulrow 1994</a>; <a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>). The main reason for this greater absolute benefit is that older people are at higher absolute risk of a cardiovascular event when compared with younger people (<a href="./references#CD000028-bbs2-0077" title="AldermanMH , MadhavanS . Management of the hypertensive patient: a continuing dilemma. Hypertension1981;3:192‐7. ">Alderman 1981</a>; <a href="./references#CD000028-bbs2-0078" title="AldermanMH . Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Annals of Internal Medicine1993;119:329‐35. ">Alderman 1993</a>; <a href="./references#CD000028-bbs2-0086" title="BrownerWS , HulleySB . Implications of hypertension trials: effect of risk status on treatment criteria. Hypertension1989;13(1):51‐6. ">Browner 1989</a>). Risk factors include pre‐existing cardiovascular disease and systolic hypertension (<a href="./references#CD000028-bbs2-0079" title="ApplegateWB , MillerST , ElamJT , CushmanWC , elDerwiD , BrewerA , GraneyMJ . Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. Archives of Internal Medicine1992;152(6):1162‐6. ">Applegate 1992</a>; <a href="./references#CD000028-bbs2-0114" title="MannSJ . Systolic hypertension in the elderly. Archives of Internal Medicine1992;152:1977‐84. ">Mann 1992</a>). </p> <p>The numbers of participants who dropped out of trials due to adverse drug effects often were not reported. The four trials that did report these data showed a significant increase in withdrawals due to adverse effects in 1000 participants. The absolute risk increase (low‐quality evidence due to substantial heterogeneity) was 10.3%, and the number needed to treat to cause one event was 10. Separate data for withdrawals due to adverse effects were not available for very elderly patients. The <a href="./references#CD000028-bbs2-0117" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a> review in younger adults aged 18 to 59 years also showed a significant increase in withdrawals due to adverse effects (RR 4.82, 95% CI 1.67 to 13.92), but the absolute increase was of a lower magnitude (3.8%) and the number needed to treat to cause one event was 27. </p> <p>Studies included in this review allowed participants in the control group to receive antihypertensive therapy because their blood pressure exceeded pre‐set "escape" criteria. Also, a portion of participants assigned to the treatment group stopped taking their assigned medication because they showed adverse drug effects, or because they achieved normal blood pressure. The degree to which participants cross over from one group to the other dilutes the results of the study. The percentage of participants assigned to the control group who were receiving antihypertensive medication by the end of the trial ranged from 9% to 53%. The percentage of participants assigned to the treatment group that had ceased taking antihypertensive medication by the end of the trial ranged from 0.5% to 63%. The impact of this cross‐over from one group to the other on the magnitude of overall effect size for all outcomes is not known. </p> <section id="CD000028-sec-0091"> <h4 class="title">Control rates</h4> <p>Control rates provide insight regarding baseline risk of study populations and can explain the differences in outcomes between individual trials. Total mortality rates in the control groups ranged from 3 to 71%. Trials with relatively low rates included <a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> (3%), <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> (5.2%), <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> (5.4%), <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> (6%), <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (6.5%), <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> (7.7%), and <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> (10.2%). Trials with moderate rates included <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> (12.3%), <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> (14.2%), <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a> (14.8%), and <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> (14.9%). Trials with relatively high rates included <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> (34.6%), <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> (35.1%), and <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> (71%). <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> and <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> did not report total mortality, but reported the second and third highest event rates (behind <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a>) in cardiovascular morbidity and mortality (<a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> 58.1%, <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> 34.3%, <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> 83.9%). </p> <p>The 95% CI for the RR of total mortality for <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> ‐ 1.11 (0.90 to 1.36) ‐ did not overlap with the 95% CI of the <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> trial ‐ 0.46 (0.29 to 0.73) ‐ in the 60‐ to 79‐year‐old subgroup. Differences in control rates are likely due to differing baseline characteristics in recruited patients. For example, all participants in <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> and in <a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> were stroke survivors. Those in <a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a> and <a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> resided in a home for the aged; patients in <a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> and <a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> were recruited from hospitals (but followed up in clinics); and participants in <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> were recruited from geriatric hospitals, physicians' offices, and homes for the aged. </p> <p>Additional explanations for differing control rates include variation in definitions of trial endpoints, cross‐over rates, and follow‐up durations. Although we attempted to standardise outcome definitions as much as possible (see <a href="#CD000028-sec-0045">Methods</a> section), truly uniform definitions between trials were not possible. Trials had cross‐over rates ranging from 9% to 62% (see <a href="./references#CD000028-sec-0123" title="">Characteristics of included studies</a>) and follow‐up durations ranging from one to six years. </p> <p>Because most data were based on healthy ambulatory patients 60 years or older and included only a small percentage of randomised participants with stroke or MI at baseline, participants with significant competing comorbidity and complicated medical regimens may show poorer compliance, less benefit, and more adverse effects compared to trial participants. </p> </section> <section id="CD000028-sec-0092"> <h4 class="title">Limitations and generalisations</h4> <p>The most appropriate way to match expected magnitude of benefit to patients with particular constellations of risk factors is to perform individual patient‐based meta‐analyses (<a href="./references#CD000028-bbs2-0099" title="GueyffierF , BoutitieF , BoisselJP , PocockS , CoopeJ , CutlerJ , et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta‐analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Annals of Internal Medicine1997;126(10):761‐7. ">Gueyffier 1997</a>). This was not possible in this review. Moreover, our aggregate results refer to generally expected benefit for hypertensive patients 60 years or older and are not tailored specifically to patients with particular risk factors. Our average results refer primarily to a primary prevention population with moderate to severe systolic or systo‐diastolic hypertension treated with a first‐line thiazide. Data for other first‐line drugs were insufficient, and the objective of this review was not to compare different first‐line drugs, which has been done by other systematic reviews (<a href="./references#CD000028-bbs2-0122" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis. JAMA1997;277(9):739‐45. ">Psaty 1997</a>; <a href="./references#CD000028-bbs2-0123" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , et al. Health outcomes associated with various antihypertensive therapies used as first‐line agents: a network meta‐analysis. JAMA2003;289(19):2534‐44. ">Psaty 2003</a>; <a href="./references#CD000028-bbs2-0145" title="WrightJM , LeeCH , ChambersKG . Systematic review of antihypertensive therapies: does the evidence assist in choosing a first‐line drug?. Canadian Medical Association Journal1999;161(1):25‐32. ">Wright JM 1999</a>; <a href="./references#CD000028-bbs2-0144" title="WrightJM , MusiniVM , GillR . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD001841.pub3] ">Wright 2018</a>). </p> <p>Actual estimates of benefits and harms of treating adults 60 years or older with hypertension, derived from trials with highly selected participants, are not readily generalisable to clinical practice and, strictly speaking, trial results cannot be generalised to such patients. Many patients would not meet eligibility criteria or, if offered the chance, would not have enrolled in a clinical trial. In practice, clinicians are of course willing to offer treatment to patients who may not have been eligible for a trial, or who, if eligible, would have refused participation, but we should approach these generalisations with forethought. Without extra care and visits provided in many trials, even our "eligible" patients may be less compliant than trial participants. Patients with significant competing comorbidities and complicated medical regimens may also have poorer compliance, less benefit, and more adverse effects compared to participants in trials. For example, in an octogenarian with orthostasis and recurring falls related to antihypertensive therapy, harms likely exceed benefits. On the other hand, clinicians should not always assume that less benefit would be seen in "real‐life" clinical settings. A person who is at high immediate risk of suffering a cardiovascular event and who does not have other competing illnesses may have a higher benefit‐to‐harm ratio than the average trial participant. </p> </section> </section> <section id="CD000028-sec-0093"> <h3 class="title" id="CD000028-sec-0093">Quality of the evidence</h3> <p>Risk of bias was assessed using the Cochrane risk of bias tool, and findings demonstrated that approximately 60% of trials had evidence of unclear risk of selection bias and 30% had high risk of selective reporting bias; also, approximately 50% of trials did not deal with missing or incomplete outcome data appropriately. In other words, 50% of trials could have censored outcome data for patients after they had their first event. In addition, in 30% of trials, when outcome data were not available, it appeared the assumption was that an event did not occur in that patient. See <a href="#CD000028-fig-0002">Figure 2</a> and <a href="#CD000028-fig-0003">Figure 3</a>. The implications are that available outcome data used in the meta‐analyses may be incomplete. It is difficult to determine whether this bias would favour treatment or control. What can be said is that reported event rates are underestimates and calculated effect sizes for outcomes (other than death as the first event) may be inaccurate. However, deselecting trials with high risk of performance and detection bias for the cardiovascular mortality and morbidity outcome increased the effect size from RR 0.72 (95% CI 0.68 to 0.77) to RR 0.66 (95% CI 0.61 to 0.72). Deselecting trials with high risk of attrition bias increased the effect size to RR 0.68 (95% CI 0.63 to 0.74). Deselecting trials with high risk of selective reporting bias also increased the effect size (RR 0.68, 95% CI 0.63 to 0.75). However, we have graded certainty for the body of evidence for cardiovascular mortality and morbidity in patients 60 years or older as moderate due to study limitations. </p> <p>Overall certainty for grading of evidence was high for all‐cause mortality and moderate for cardiovascular mortality and morbidity outcomes in patients 60 years or older. The interpretation of high certainty is that we are very confident that the true effect lies close to that of the estimate of the effect. The interpretation of moderate certainty is that we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low‐certainty evidence was noted for withdrawal due to adverse effects. The interpretation of low‐certainty evidence is that we have very little confidence in the effect estimate and the true effect is likely to be substantially different from the estimate of the effect. </p> </section> <section id="CD000028-sec-0094"> <h3 class="title" id="CD000028-sec-0094">Potential biases in the review process</h3> <p>Obtaining data from all available trials in adults with hypertension may improve the effect estimate and may yield evidence of high certainty. Most trials in patients with hypertension include adults 18 years or older but do not report data in subgroups based on age (18 to 59 years old; 60 to 79 years old; and the very elderly 80 years or older). Although 15 additional trials met the minimum inclusion criteria of this review, data from these studies for patients 60 years or older could not be included (see <a href="#CD000028-tbl-0002">Table 1</a>). We would like to encourage researchers to provide access to data on subgroups of older patients in trial populations, either by providing aggregate data for participants age 60 years or older, or by providing individual patient data, so we can include these trials in a future update. </p> <p>The main limitation of this meta‐analysis is the heterogeneity of the studies included. Other limitations common to all meta‐analyses include publication bias and lack of individual patient data. </p> </section> <section id="CD000028-sec-0095"> <h3 class="title" id="CD000028-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>The <a href="./references#CD000028-bbs2-0121" title="PearceKA , FurbergCD , RushingJ . Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life?. Archives of Family Medicine1995;4(11):943‐50. ">Pearce 1995</a> systematic review evaluated short‐term benefit of drug treatment for hypertension or placebo in the elderly 60 years or older for stroke, major coronary events, and mortality rates. These review authors included eight RCTs in 15,990 patients treated on average for 4.9 years (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981;</a><a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986;</a><a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989;</a><a href="./references#CD000028-bbs2-0030" title="Hypertension Detection and Follow‐up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(2 Pt 2):I198‐206. ">HDFP 1984;</a><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989;</a><a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>). Mean baseline blood pressure was 179/90 mmHg, with a mean treatment effect of 15/6 mmHg. Reduction was observed in fatal or non‐fatal major coronary events of 0.82 (0.73 to 0.92); fatal or non‐fatal stroke 0.65 (0.57 to 0.75); and death from any cause 0.85 (0.78 to 0.92) (P &lt; 0.005 for each). These review authors concluded, similarly to us, that antihypertensive treatment in the elderly prevents major coronary events and stroke and prolongs life, with significant treatment effects observed within five years. </p> <p><a href="./references#CD000028-bbs2-0124" title="QuanA , KerlikowskeK , GueyffierF , BoisselJP . Efficacy of treating hypertension in women. Journal of General Internal Medicine1999;14(12):718‐29. ">Quan 1999</a> systematically reviewed 11 RCTs from 1966 to 1998 in &gt; 100 women with hypertension that compared single or multiple antihypertensive treatment versus placebo or standard care to evaluate cardiovascular mortality and morbidity outcomes according to gender, race, or both (<a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a>; <a href="./references#CD000028-bbs2-0022" title="CasigliaE , SpolaoreP , MazzaA , GinocchioG , ColangeliG , OnestoC , et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Japanese Heart Journal1994;35(5):589‐600. ">CASTEL 1994</a>; <a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0030" title="Hypertension Detection and Follow‐up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(2 Pt 2):I198‐206. ">HDFP 1984</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). In women aged 55 years or older (90% white), hypertension treatment resulted in a 38% risk reduction in fatal and non‐fatal cerebrovascular events (95% CI 27% to 47%; 5‐year NNTB 78), a 25% reduction in fatal and non‐fatal cardiovascular events (95% CI 17% to 33%; 5‐year NNTB 58), and a 17% reduction in cardiovascular mortality (95% CI 3% to 29%; 5‐year NNTB 282). Review authors concluded that hypertension treatment lowers the relative and absolute risk of cardiovascular morbidity and mortality in women aged 55 years and older and in African American women of all ages. </p> <p>The <a href="./references#CD000028-bbs2-0096" title="GoeresLM , EckstromE , LeeDS . Pharmacology for hypertension in older adults: a systematic review. Drugs and Aging2014;31:897‐910. ">Goeres 2014</a> systematic review included 19 studies (N = 55,489) from 1996 to 2014, consisting of seven studies comparing antihypertensive treatment to placebo or no treatment (N = 17,206) (<a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>), along with 12 head‐to‐head comparator trials (N = 38,283). Review authors concluded that older adults ≥ 65 years had decreased cardiovascular mortality and morbidity with antihypertensive treatment compared with no treatment. There was enormous heterogeneity in these studies, and reporting of harms stratified by age was lacking. They also concluded that current evidence was insufficient to determine the safest, most beneficial hypertension regimen for older adults. </p> <p><a href="./references#CD000028-bbs2-0119" title="ParsonsC , MuradMH , AndersenS , MookadamF , LabonteH . The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta‐analysis. Future Cardiology2016;12(2):237‐48. ">Parsons 2016</a> conducted a systematic review of nine randomised placebo‐controlled trials in which hypertensive patients with mean age ≥ 65 years received antihypertensive or control treatment for a minimum duration of 2 years (<a href="./references#CD000028-bbs2-0094" title="ZhangY , ZhangX , LiuL , ZanchettiA , Group FS. Is a systolic blood pressure target &lt; 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomised FEVER trial. European Heart Journal2011;32(12):1500‐8. ">FEVER 2011</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD000028-bbs2-0064" title="LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double‐blind intervention trial. Journal of Hypertension2003;21(5):875‐86. [DOI: 10.1097/01.hjh.0000059028.82022.89] ">SCOPE 2003</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0066" title="GongL , ZhangW , ZhuY , ZhuJ , KongD , PageV , et al. Shanghai trial of nifedipine in the elderly (STONE). Journal of Hypertension1996;14(10):1237‐45. ">STONE 1996</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0069" title="Anonymous . Systolic hypertension in the elderly: Chinese trial (Syst‐China) ‐ second interim report. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]1993;21(3):135‐7,185. Anonymous . [Systolic hypertension in the elderly: Chinese trial (Syst‐China). Interim report]. [Chinese] Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]1992;20(5):270‐5,323. ">Syst‐China 1993</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). They concluded that antihypertensive treatment reduced the risk of stroke (RR 0.67, 95% CI 0.57 to 0.79) including fatal and non‐fatal stroke and transient ischaemic attacks. Reduction in dementia and cognitive decline was not significant. </p> <p><a href="./references#CD000028-bbs2-0083" title="Bejan‐AngoulvantT , Saadatian‐ElahiM , WrightJM , SchronEB , LindholmLH , FagardR , et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta‐analysis of randomized controlled trials. Journal of Hypertension2010;28(7):1366‐72. ">Bejan‐Angoulvant 2010</a> explored heterogeneity using meta‐regression in patients 80 years or older based on the same eight RCTs in 6701 patients included in our review (<a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a>; <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a>; <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>; <a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a>; <a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a>; <a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a>). There was significant heterogeneity between <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> and other trials. Mean SBP at entry was 173 mmHg in the <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> population and about 180 mmHg in the remaining trials. In the <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> study, the percentage of patients with history of diabetes was lower (6.9% vs 14%), history of previous stroke was higher (6.8% vs 4%), and previous hypertension treatment was more frequent (65% vs 34%) in comparison with the other included trials. Other trials recruited most patients from Europe and the USA. However, more than one‐third of the <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> population was recruited in China. Chinese patients had significantly lower body mass index (BMI), lower sitting DBP, lower total cholesterol, higher high‐density lipoprotein (HDL) cholesterol, and better renal function. Previous episodes of myocardial infarction and congestive heart failure were significantly fewer among Chinese. The estimated annual mortality rate in control groups varied from 3.4% in <a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a> to 15.4% in <a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> and to 6% in <a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>. Despite meta‐analysis of the best evidence for patients 80 years or older showing reduction in stroke and heart failure, a reduction in mortality was not observed. This heterogeneity was not explained by differences in follow‐up duration between trials. The meta‐regression suggested that reduction in mortality was achieved in trials with the least blood pressure (BP) reduction and the lowest intensity of therapy. This has led to the recommendation that people over 80 should be treated with low doses of a thiazide and angiotensin‐converting enzyme (ACE) inhibitor, as was used in the only trial associated with a reduction in mortality (<a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a>). These observations suggest that less aggressive treatment is probably a good approach in the very elderly. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000028-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000028-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: Each methodological quality item presented as percentages across all included studies." data-id="CD000028-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: Each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary of each included trial." data-id="CD000028-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary of each included trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antihypertensive drug therapy vs control in adults 60 years or older, outcome: 1.2 Cause of cardiovascular mortality." data-id="CD000028-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antihypertensive drug therapy vs control in adults 60 years or older, outcome: 1.2 Cause of cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 1 Total mortality." data-id="CD000028-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 1 Total mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 2 Cause of cardiovascular mortality." data-id="CD000028-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 2 Cause of cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 3 Cardiovascular mortality and morbidity." data-id="CD000028-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 3 Cardiovascular mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 4 Cerebrovascular mortality and morbidity." data-id="CD000028-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 4 Cerebrovascular mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 5 Coronary heart disease mortality and morbidity." data-id="CD000028-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 5 Coronary heart disease mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 6 Withdrawal due to adverse effects." data-id="CD000028-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antihypertensive drug therapy vs control in adults 60 years or older, Outcome 6 Withdrawal due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 1 Total mortality." data-id="CD000028-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 1 Total mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 2 Cardiovascular mortality and morbidity." data-id="CD000028-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 2 Cardiovascular mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 3 Cerebrovascular mortality and morbidity." data-id="CD000028-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 3 Cerebrovascular mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 4 Coronary heart disease mortality and morbidity." data-id="CD000028-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older), Outcome 4 Coronary heart disease mortality and morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 1 Total mortality." data-id="CD000028-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 1 Total mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 2 Cardiovascular morbidity and mortality." data-id="CD000028-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 2 Cardiovascular morbidity and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 3 Cerebrovascular morbidity and mortality." data-id="CD000028-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 3 Cerebrovascular morbidity and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 4 Coronary heart disease morbidity and mortality." data-id="CD000028-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 4 Coronary heart disease morbidity and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000028-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/urn:x-wiley:14651858:media:CD000028:CD000028-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_t/tCD000028-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 5 Withdrawal due to adverse effects 60 years or older." data-id="CD000028-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension, Outcome 5 Withdrawal due to adverse effects 60 years or older. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/media/CDSR/CD000028/image_n/nCD000028-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000028-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug compared to placebo or no treatment in adults 60 years or older</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to placebo or no treatment in adults 60 years or older</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults 60 years or older with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> <p>(93 to 106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91 (0.85 to 0.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,932<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1%<br/> NNTB = 100 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 3.7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> <p>(92 to 104)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72 (0.68 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,747<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.8%<br/> NNTB = 27 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 3.7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> <p>(31 to 39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.59 to 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,042<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.8%<br/> NNTB = 56 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 2.9 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> <p>(33 to 42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78 (0.69 to 0.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,559<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.1%<br/> NNTB = 91 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse effects</p> <p>Mean duration of 4.6 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> <p>(138 to 178)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.91 (2.56 to 3.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,310<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 10.3%<br/> NNTH = 10 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARI: absolute risk increase; ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to study limitations (incomplete outcome reporting and selective outcome reporting). </p> <p><sup>b</sup>Downgraded due to high risk of selective reporting bias, as only 4 out of 16 included RCTs reported this outcome. </p> <p><sup>c</sup>Downgraded due to inconsistency (I² &gt; 50%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antihypertensive drug compared to placebo or no treatment in adults 60 years or older</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000028-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs meeting the minimum inclusion criteria but not providing data in patients ≥ 60 with hypertension</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0076" title="The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE I) Investigators. Irbesartan in patients with atrial fibrillation. New England Journal of Medicine2011;364:928‐33. ">ACTIVE I</a> 2<a href="./references#CD000028-bbs2-0076" title="The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE I) Investigators. Irbesartan in patients with atrial fibrillation. New England Journal of Medicine2011;364:928‐33. ">011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised trial comparing irbesartan 300 mg/d or double‐blind placebo in patients 55 years or older for a mean follow‐up of 4.1 years. 52% of patients had hypertension at baseline. Data are not available for hypertensive patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0081" title="BarracloughM , BaintonD , CochraneAL , et al. Control of moderately raised blood pressure: report of a co‐operative randomized controlled trial. BMJ1973;3(5877):434‐6. ">Barraclough 1973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind randomised placebo‐controlled trial in patients 45 to 69 years old for a mean follow‐up of 1.5 years. Data for 60‐ to 69‐year‐old patients are not available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0087" title="BullS , LoudonM , FrancisJM , JosephJ , GerryS , KaramitsosTD , et al. A prospective, double‐blind, randomized controlled trial of the angiotensin‐converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). European Heart Journal Cardiovascular Imaging2015;16(8):834‐41. ">Bull 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial in adult patients 18 years or older with moderate or severe asymptomatic aortic stenosis. 32% of patients had hypertension at baseline. Participants were randomised to ramipril 10 mg daily or placebo for 1 year. Data are not reported separately in hypertensive subgroup of patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0091" title="DREAM Trial Investigators, BoschJ , YusufS , GersteinHC , PogueJ , SheridanP , et al. Effect of ramipril on the incidence of diabetes. New England Journal of Medicine2006;355(15):1551‐62. ">DREAM 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT in participants 30 years or older without cardiovascular disease but with impaired fasting glucose levels (after an 8‐hour fast) or impaired glucose tolerance. Participants were randomised to ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and were followed for a median of 3 years. 43.7% of patients at baseline had a history of hypertension. Data are not reported for patients with hypertension who were 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0093" title="DUTCH ‐TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">DUTCH ‐TIA 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind trial comparing atenolol 50 mg daily to placebo in patients 65 years or older who had a TIA for a mean follow‐up period of 2.6 years. Data for those 60 and over with hypertension at baseline were not available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0103" title="YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. ">HOPE‐HYP 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT in patients 55 years or older with previous coronary artery disease, cerebrovascular disease, or peripheral vascular disease or diabetes plus one additional risk factor. Participants randomised to ramipril 2.5 mg titrated up to 0 mg/d or placebo. Average follow‐up was 4.5 years. Data are not reported separately for people 60 years or older with hypertension </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0107" title="The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta‐blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension1985;3(4):379‐92. ">IPPPSH 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised trial in 40‐ to 64‐year‐old patients with hypertension randomised to oxprenolol or placebo for a mean follow‐up of 3.5 years. Data are not reported separately for participants 60 to 64 years of age </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0115" title="MatersonBJ , RedaDJ , CushmanWC , MassieBM , FreisED , KocharMS , et al. Single‐drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. New England Journal of Medicine1993;328(13):914‐21. ">Materson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled study of male veterans 21 years or older with DBP of 95 to 109 mmHg. Participants randomised to placebo or to 1 of the 6 drugs ‐ HCTZ 12.5 to 50 mg/d; atenolol 25 to 100 mg/d; captopril 25 to 100 mg/d; clonidine 0.2 to 0.6 mg/d; sustained preparation of diltiazem 120 to 360 mg/d; or prazosin 4 to 20 mg/d ‐ for a period of 1 year. Morbidity and mortality outcomes not reported for different drug classes nor for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0120" title="PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. ">PATS 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in Chinese patients with mean age 60 ± 8 years. Participants were randomised to indapamide 2.5 mg/d or placebo. Data are not reported separately for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0132" title="ErikssonS , OlofssonBO , WesleyPO , et al. Atenolol for secondary prevention after stroke. Cerebrovascular Disease1995;5:21‐5. ">TEST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in 720 Swedish patients &gt; 40 years old, within 3 weeks of a stroke or transient ischaemic attack with a mean follow‐up period of 30 months. Data are not reported separately for patients 60 years or older </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0137" title="ElmerPJ , GrimmR , LaingB , GranditsG , SvedsenK , VanHeelN , et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Preventive Medicine1995;24(4):378‐88. ">TOMHS 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four‐year double‐blind placebo‐controlled randomised trial in patients with mild hypertension (average blood pressure, 140/91 mmHg) aged 45 to 69 years. Participants randomised to receive nutritional‐hygienic intervention plus 1 of 6 treatments: (1) placebo; (2) diuretic (chlorthalidone); (3) beta blocker (acebutolol); (4) alpha 1 antagonist (doxazosin mesylate); (5) calcium antagonist (amlodipine maleate); or (6) angiotensin‐converting enzyme inhibitor (enalapril maleate). Morbidity and mortality events were not reported separately for the different drug treatments. Corresponding author was contacted, but data for 60‐ to 69‐year‐old patients were not provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0139" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998;317(7160):713‐20. ">UKPDS 39 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised controlled open‐label trial conducted in newly diagnosed patients 25 to 65 years old with type 2 diabetes mellitus and hypertension. Participants were randomised to captopril or atenolol or placebo and were followed for 8.4 years. Data for patients 60 to 65 years old are not reported separately </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0140" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, clorisondamine, mecamylamine, and pentolinium tartrate. Archives of Internal Medicine1962;110(2):222‐29. ">VA Coop 1962</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled study of 1 year's duration in 759 hypertensive patients. The study recruited men less than 70 years old. This study did not report results separately for those 60 to 69 years old </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0141" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐34. ">VA‐I 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised double‐blind placebo‐controlled trial conducted in ambulatory patients in the USA with mean age 51 years. Age range not reported. Participants were randomised to hydrochlorothiazide 100 mg plus reserpine 0.2 mg plus hydralazine 75 mg or 150 mg or placebo. Mean follow‐up was 1.5 years. Data for patients 60 years or older are not reported separately </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000028-bbs2-0143" title="WolfFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. Journal of Chronic Diseases1966;19(3):227‐40. ">Wolf 1966</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind placebo‐controlled trial conducted in ambulatory patients in the USA with mean age 50 years. Participants were randomised to reserpine 0.25 mg t.i.d., chlorothiazide 0.5 g b.i.d., or hydrochlorothiazide 25 mg q.i.d. plus guanethidine if needed or placebo. Mean follow‐up was 2 years. Data for patients 60 years or older are not reported separately </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>DBP: diastolic blood pressure.</p> <p>HCTZ: hydrochlorothiazide.</p> <p>RCT: randomised controlled trial.</p> <p>TIA: transient ischaemic attack.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">RCTs meeting the minimum inclusion criteria but not providing data in patients ≥ 60 with hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000028-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Details of studies meeting the inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>(N = randomised 60 years or older)</b> </p> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline SBP/DBP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> <p><b>(range), years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Antihypertensive drug treatment used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0001" title="A report by the Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Clinical Science1979;57(Suppl 5):449s‐52s. [MEDLINE: 80155869] A report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet1980;1(8181):1261‐7. A report by the Management Committee. The Australian therapeutic trial in mild hypertension. The Lancet1980;1:1261‐7. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] A study initiated and administered by the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Medical Journal of Australia1981;2(8):398‐402. AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1981</a> </p> <p><b>(N = 582)</b> </p> <p><b>Double‐blind</b> </p> <p><b>(identified as ANBP 1981 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> <p>(60 to 69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ chlorothiazide 500 mg, second‐line ‐ dose increased to 1000 mg, or addition of methyldopa, propranolol, or pindolol. Third‐line drugs added were hydralazine or clonidine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0002" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1(7645):485‐9. ">Carter 1970</a> </p> <p><b>(N = 48)</b> </p> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> <p>(60 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> <p>(untreated control group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bendrofluazide (93%), methyldopa, and debrisoquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0003" title="CoopeJ , WarrenderTS . Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ1986;293:1145‐52. ">Coope 1986</a><sup>a</sup> </p> <p><b>(N = 884)</b> </p> <p><b>Open‐label</b> </p> <p><b>(identified as HEP 1986 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196/99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> <p>(60 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ atenolol 100 mg daily; second‐line ‐ bendrofluazide 5 mg daily; third‐line ‐ methyldopa 500 mg daily; fourth‐line ‐ any recognised therapy </p> <p>In the last 2 years of the trial, several participants were treated with nifedipine retard 20 mg morning and night </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0004" title="AmeryA , BerthauxP , BirkenhagerC , BulpittC , ClementD , DeShaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BerthauxP , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years (Fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Clinical Science and Molecular Medicine1978;55(Suppl 4):263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxW , BirkenhagerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly (EWPHE). Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP . Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High Blood Pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(Suppl 6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhagerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(3):S501‐11. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicentre trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl 1):71s‐3s. AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressuire in the Elderly. American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives Internationales de Pharmacodynamie et de Therapie1985;275(2):300‐34. European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on High Blood Pressure in the Elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhagerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy1990;4(Suppl 6):1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(Suppl 1):S105‐8. PrisantLM , CarrAA . Overview of the findings of the European Working Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the EWPHE trial. American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the EWPHE. American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA . Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the EWPHE. American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine1991;90(Suppl 3A):55s‐9s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardL , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHBPE 1989</a> </p> <p><b>(N = 840)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ hydrochlorothiazide 25 to 50 mg + triamterene 50 to 100 mg daily; second‐line ‐ methyldopa 250 to 2000 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0005" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> </p> <p><b>(N = 200)</b> </p> <p><b>Double‐blind</b> </p> <p><b>(identified as HTN‐COOP 1976 in original Mulrow review)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deserpidine 1 mg plus methyclothiazide 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0006" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. ">HYVET 2008</a> </p> <p><b>(N = 3845)</b> </p> <p><b>Double‐blind</b> </p> <p><b>80 years or older</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> <p>(80 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line‐ indapamide 1.5 mg daily; second‐line ‐ perindopril 2 mg daily; third‐line ‐ perindopril 4 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0007" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ , et al. Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumiktrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET P 2003</a> </p> <p><b>(N = 1283)</b> </p> <p><b>Open‐label</b> </p> <p><b>80 years or older</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182/100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> <p>(80 to 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ diuretic (usually bendrofluazide 2.5 mg), an ACE inhibitor (usually lisinopril 2.5 mg), or no treatment; second‐line ‐ involved doubling the dose of the first drug; third‐line ‐ involved adding diltiazem slow‐release 120 mg daily; fourth‐line ‐ involved adding diltiazem slow‐release 240 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0008" title="KuramotoK , MatsushitaS , KuwajimaT , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22(1):75‐85. ">Kuramoto 1981</a> </p> <p><b>(N = 91)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> <p>(&gt; 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ trichlormethiazide 1 to 4 mg; 80% monotherapy;</p> <p>second‐line ‐ reserpine (0.3 mg), methyldopa (125 to 500 mg), and hydralazine (50 to 100 mg) added </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0009" title="MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ1992;304(6824):405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> </p> <p><b>(N = 4396)</b> </p> <p><b>Single‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> <p>(60 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic arm:</p> <p>First‐line ‐ hydrochlorothiazide 25 mg or 50 mg + amiloride 2.5 mg or 5 mg daily; second‐line ‐ atenolol 50 mg daily; </p> <p>third‐line ‐ nifedipine up to 20 mg daily; fourth‐line ‐ other drugs</p> <p>Beta blocker arm:</p> <p>First‐line ‐ atenolol 50 mg daily; second‐line ‐ hydrochlorothiazide 25 mg or 50 mg + amiloride 2.5 mg or 5 mg daily; third‐line ‐ nifedipine up to 20 mg daily; fourth‐line ‐ other drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0010" title="Anonymous. Report of the Medical Research Council Working party on mild to moderate hypertension. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. BMJ1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal Clinical Research Ed.1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. BMJ1986;293(6553):988‐92. [MEDLINE: 87027367] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> </p> <p><b>60‐ to 64‐year‐old subgroup</b> </p> <p><b>(N = 2813)</b> </p> <p><b>Single‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in this subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bendrofluazide 10 mg daily, propranolol 80 to 240 mg daily; methyldopa added if required</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0011" title="ApplegateWB , DavisBR , BlackHR , SmithWM , MillerST , BurlandoAJ . Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. Journal of American Geriatric Society1991;39(11):1057‐64. [MEDLINE: 92091624] ApplegateWB , PresselS , WittesJ , LuhrJ , ShekelleRB , CamelGH , et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Archives of Internal Medicine1994;154(19):2154‐60. BeardenD , AllmanR , McDonaldR , MillerS , PresselS , PetrovichH . Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. Journal of the American Geriatric Society1994;42:1143‐9. [MEDLINE: 95052246] BlackHR , UngerD , BurlandoA , WrightJC , PresselSL , AllenR , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 6: Baseline physical examination findings. Hypertension1991;17(3 Suppl):II‐77‐101. [MEDLINE: 91153895] BorhaniNO , ApplegateWB , CutlerJA , DavisBR , FurbergCD , LakatosE , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension1991;17(3 Suppl):II2‐15. [MEDLINE: 91153891] BrittainE , PalenskyJ , Blood J, WittesJ . Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). Statistics in Medicine1997;16(6):681‐93. [MEDLINE: 97278485] CurbJD , LeeM , JensenJ , ApplegateW . Systolic Hypertension in the Elderly Program (SHEP). Part 4: Baseline medical history findings. Hypertension1991;17(3 Suppl):II35‐61. [MEDLINE: 91153893] CurbJD , PresselSL , CutlerJA , SavagePJ , ApplegateWB , BlackH , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276(23):1886‐92. [MEDLINE: 97122394] DavisBR , Wittes J. PresselS , BergeKG , HawkinsCM , LakatosE , et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Controlled Clinical Trials1993;14(5):350‐61. [MEDLINE: 94038014] FranseLV , Pahor M. Di BariM , ShorrRI , WanJY , SomesGW , et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of Hypertension2000;18(8):1149‐54. FrostPH , DavisBR , BurlandoAJ , CurbJD , GuthrieJPJr , IsaacsonJL , et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94(10):2381‐8. [MEDLINE: 97080432] HallWD , DavisBR , FrostP , HoffmeierM , O'BrienJE , PaceS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 Suppl):II102‐22. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: the SHEP experience. American Journal of Geriatric Cardiology1993;2(5):25‐7. HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. KostisJB , AllenR , BerksonDM , CurbJD , DaveyJ , GrimmRH , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127(1):112‐21. [MEDLINE: 94099287] KostisJB , DavisBR , CutlerJ , BergeKG , CohenJD , LacyCR , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐16. [MEDLINE: 97361706] KostisJB , LacyCR , HallD , WilsonAC , BorhaniNO , KriegerSD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74(5):464‐7. [MEDLINE: 94337726] KostisJB , PrineasR , CurbJD , LeeM , BerksonD , RainesJ , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 Suppl):II123‐51. [MEDLINE: 91153887] MenardJ , DayM , ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5(5 Pt 1):325‐30. [MEDLINE: 92255887] NewmanAB , TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of the American Geriatrics Society1997;45(12):1472‐78. [MEDLINE: 98063204] PerryHMJr , DavisBR , PriceTR , ApplegateWB , FieldsWS , GuralnikJM , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐71. PetrovichH , ByingtonR , BaileyG , BorhaniP , CarmodyS , GoodwinL , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: screening and recruitment. Hypertension1991;17(3 Suppl):II17‐23. [MEDLINE: 91153889] ProbstfieldJL . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Annals of Internal Medicine1991;115(Suppl 3):65. ProbstfieldJL , ApplegateWB , BorhaniNO , CurbJD , CutlerJA , DavisBR , et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clinical &amp; Experimental Hypertension ‐ Part A, Theory &amp; Practice1989;11(5‐6):973‐89. [MEDLINE: 90003847] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265(24):3255‐64. SavagePJ , PresselSL , CurbD , SchronEB , ApplegateWB , BlackHR , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine1998;158(7):741‐51. [MEDLINE: 98213401] The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐208. VogtTM , SchronE , PresselS , Wasserthiel‐SmollerS , EddlemanEE , MillerS , et al. Systolic Hypertension in the Elderly Program (SHEP). Part 3: sociodemographic characteristics. Hypertension1991;17(3 Suppl):II‐24‐34. [MEDLINE: 91153892] Wassertheil‐SmollerS , ApplegateWB , BergeK , ChangCJ , DavisBR , GrimmRJr , et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Archives of Internal Medicine1996;156(5):533‐61. [MEDLINE: 96178910] Wasserthell‐SmollerS , FannC , AllmanRM , BlackHR , CamelGH , DavisB , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Archives of Internal Medicine2000;160(4):494‐500. [MEDLINE: 20158236] WeilerPG , CamelGH , ChiappiniM , GreenlickMR , HughesGH , LuhrJC , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 9: behavioral characteristics. Hypertension1991;17(3 Suppl):II152‐61. [MEDLINE: 20158236] WittesJ , DavisB , BergeK , CohenJD , GrimmRHJr , HawkinsCM , et al. Systolic Hypertension of the Elderly Program (SHEP). Part 10: analysis. Hypertension1991;17(3 Suppl):II162‐7. [MEDLINE: 91153890] ">SHEP 1991</a> </p> <p><b>(N = 4736)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>170/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ chlorthalidone 12.5 or 25 mg daily; second‐line ‐ atenolol 25 or 50 mg or reserpine 0.05 or 0.10 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0012" title="BlackDM , BrandRJ , GreenlickM , HughesG , SmithJ . Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. Journal of Gerentology1987;42(5):552‐7. [MEDLINE: 87309619] FurbergCD , BlackDM . The systolic hypertension in the elderly pilot program: methodological issues. European Heart Journal1988;9(2):223‐7. [MEDLINE: 88166820] HulleySB , FeigalD , IrelandC , KullerLH , SmithWM . Systolic hypertension in the elderly program (SHEP). The first three months. Journal of the American Geriatrics Society1986;34(2):101‐105. [MEDLINE: 86113041] HulleySB , FurbergCD , GurlandB , McDonaldR , PerryHM , SchnaperHW , et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology1985;56(15):913‐20. PerryHM , McDonaldRH , HulleySB , SmithWM , FurbergCD , GreenlickMR . Systolic Hypertension in the Elderly Program, Pilot Study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(6):S21‐3. PerryHM , SmithWM , McDonaldRH , BlackD , CutlerJA , FurbergCD , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. Stroke1989;20(1):4‐13. VogtTM , IrelandCC , BlackD , CamelG , HughesG . Recruitment of elderly volunteers for a multicenter clinical trial: the SHEP pilot study. Controlled Clinical Trials1986;7(2):118‐33. [MEDLINE: 86299645] VogtTM , IrelandCC , GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP pilot trial. American Journal of Preventive Medicine1988;4(1):1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> </p> <p><b>(N = 551)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172/75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fisrt‐line ‐ chlorthalidone 25 to 50 mg daily (87%); second‐line ‐ hydralazine 25 mg twice daily, reserpine 0.05 mg twice daily, or metoprolol 50 mg twice daily (13%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0013" title="SpracklingME , MitchellJRA , ShortAH , WattG . Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ1981;283:1151‐3. ">Sprackling 1981</a><sup>a</sup> </p> <p><b>(N = 123)</b> </p> <p><b>Open‐label</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199/106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methyldopa 250 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0014" title="DahlofB , LindholmLH , HanssonL , ScherstenB , EkbomT , WesterPO . Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP‐Hypertension). Lancet1991;338(8778):1281‐5. ">STOP 1991</a><sup>a</sup> </p> <p><b>(N = 1627)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> <p>(70 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ atenolol 50 mg daily or hydrochlorothiazide 25 mg + amiloride 2.5 mg daily, or metoprolol 100 mg daily, or pindolol 5 mg daily; second‐line ‐ patients on a beta blocker received diuretics, and those on diuretics received a beta blocker </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0015" title="AmeryA , BirkenhagerW , BulpittCJ , ClementD , DeLeeuwP , FagardR , et al. Syst‐Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. BirkenhagerWH , StaessenJ , GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13(3):323‐37. CelisH , YodfatY , ThijsL , ClementD , CozicJ , DeCortP , et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst‐Eur experience in general practice. The Syst‐Eur Investigators. Family Practice1996;13(2):138‐43. GasowskiJ , BirkenhagerWH , StaessenJ , DeLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP , et al. SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report [SYST‐EUR un essai multicentrique du traitement de l'hypertension systolique du sujet age. Premier rapport intermediaire]. Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. Journal of Human Hypertension1993;7(2):201‐3. StaessenJ , BertP , BulpittC . de Cort P, Fagard R, Fletcher A, et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. Journal of Human Hypertension1993;7(3):265‐71. StaessenJ , DekempeneerL , FagardR , GuoCY , ThijsL , vanHoofR , et al. Treatment of isolated systolic hypertension in the elderly. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐40. [MEDLINE: 92139861] StaessenJA , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , DeLeeuwP , et al. Syst‐Eur ‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19(1):120‐5. [MEDLINE: 92278050] StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhagerWH , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Lancet1997;350(9080):757‐64. StaessenJA , FagardR , Thijs L. CelisH , BirkenhagerWH , BulpittCJ , et al. Subgroup and per‐protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine1998;158(15):1681‐91. [MEDLINE: 98364833] StaessenJA , ThijsL , BieniaszewskiL , O'BrienET , PalatiniP , DavidsonC , et al. Ambulatory monitoring uncorrected for placebo overestimates long‐term antihypertensive action. Systolic Hypertension in Europe (SYST‐EUR) Trial Investigators. Hypertension1996;27(3 Pt 1):414‐20. StaessenJA , ThijsL , ClementD , DavidsonC , FagardR , LehtonenA , et al. Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. Syst‐Eur Investigators. Journal of Hypertension1994;12(9):1035‐9. StaessenJA , ThijsL , ManciaG , ParatiG , O'BrienET . Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst‐Eur Investigators. Lancet1994;344(8936):1552‐6. ThijsL , DabrowskaE , ClementD , FagardR , LaksT , ManciaG , et al. Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST‐EUR Investigators. Journal of Human Hypertension1995;9(11):917‐24. ">Syst‐Eur 1991</a> </p> <p><b>(N = 4695)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> <p>(60 or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ nitrendipine 10 mg daily, 10 mg BID, 20 mg BID;</p> <p>second‐line ‐ enalapril 5 mg, 10 mg, 20 mg daily in evening and/or hydrochlorothiazide 12.5 to 25 mg/d in morning </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000028-bbs2-0016" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation1972;45(5):991‐1004. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213(7):1143‐52. [MEDLINE: 70243223] ">VA‐II 1970</a> </p> <p><b>(N = 81)</b> </p> <p><b>Double‐blind</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> <p>(60 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line ‐ HCTZ 100 mg plus reserpine 0.2 mg; second‐line ‐ hydralazine 75 to 150 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality and morbidity</p> <p>Cerebrovascular mortality and morbidity</p> <p>CHD mortality and morbidity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A total of 16 trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 26,795</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SBP ranged from 165 to199 mmHg and DBP from 75 to 106 mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age 64 to 84 years;</b> </p> <p><b>age ranged from 60 to 105 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 placebo‐controlled studies;</b> </p> <p><b>4 studies with observation as control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drugs used included thiazides, beta blockers, calcium channel blockers, ACE inhibitors, methyldopa, reserpine, hydralazine, and clonidine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Studies with baseline SBP &gt; 190 mmHg. </p> <p>ACE: angiotensin‐converting enzyme.</p> <p>CHD: coronary heart disease.</p> <p>DBP: diastolic blood pressure.</p> <p>SBP: systolic blood pressure.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Details of studies meeting the inclusion criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000028-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 60 to 79 years old with hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control in adults 60 to 79 years old with hypertension</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy ambulatory adults 60 to 79 years old with hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Fixed‐effect model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 4.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (75 to 90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86 (0.79 to 0.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,017<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.4%<br/> NNTB = 72 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/> (85 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (0.65 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,484<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.8%<br/> NNTB = 27 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (29 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.58 to 0.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,484<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.7%<br/> NNTB = 59 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 4.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (36 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (0.69 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,284<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.1%<br/> NNTB = 91 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to study limitations (incomplete outcome reporting and selective outcome reporting). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 60 to 79 years old with hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000028-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 80 years or older with hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihypertensive drug therapy compared to control in adults 80 years or older with hypertension</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy ambulatory adults 80 years or older with hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> antihypertensive drug therapy<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>Random‐effects model</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antihypertensive</b> </p> <p><b>drug therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total mortality</p> <p>Mean duration of 2.3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> <p>(124 to 157)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97 (0.87 to 1.10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6701<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality and morbidity</p> <p>Mean duration of 2.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/> (75 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.75 (0.65 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6546<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.9%<br/> NNTB = 35 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular mortality and morbidity</p> <p>Mean duration of 2.2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/> (27 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.52 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6546<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.7%<br/> NNTB = 59 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary heart disease mortality and morbidity</p> <p>Mean duration of 2.5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (12 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (0.56 to 1.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5263<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ARR: absolute risk reduction; CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to inconsistency and wide confidence interval. </p> <p><sup>b</sup>Downgraded due to study limitations ‐ high risk of selective reporting bias in HYVET 2008 study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Antihypertensive drug therapy compared to control in adults 80 years or older with hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/full#CD000028-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000028-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihypertensive drug therapy vs control in adults 60 years or older</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cause of cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.54, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fatal CHD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.68, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cerebrovascular mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.59, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Coronary heart disease mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [2.56, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihypertensive drug therapy vs control in adults 60 years or older</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000028-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.79, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cerebrovascular mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.58, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Coronary heart disease mortality and morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.69, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihypertensive drug therapy vs control according to subgroup (60 to 79 years old and 80 years or older)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000028-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.88, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular morbidity and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.56, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cerebrovascular morbidity and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.50, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.40, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Coronary heart disease morbidity and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 60 to 79 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 80 years or older</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to adverse effects 60 years or older <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.53, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antihypertensive drug therapy vs control in adults 60 years or older with isolated systolic hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000028.pub3/references#CD000028-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000028.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000028-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000028-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000028-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000028-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000028-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD000028-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD000028-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD000028-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000028-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000028-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000028\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000028\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000028\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000028\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000028\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000028.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000028.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000028.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000028.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000028.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715895914"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000028.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715895918"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000028.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d92442ebf9368',t:'MTc0MDcxNTg5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 